



Universiteit
Leiden
The Netherlands

Concepts and applications for evidence-based dosing in morbidly obese patients before and after weight loss surgery

Brill, Margreke Jantine Eltje

Citation

Brill, M. J. E. (2015, December 3). *Concepts and applications for evidence-based dosing in morbidly obese patients before and after weight loss surgery*. Retrieved from <https://hdl.handle.net/1887/36511>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/36511>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/36511> holds various files of this Leiden University dissertation

Author: Brill, Margreke

Title: Concepts and applications for evidence-based dosing in morbidly obese patients before and after weight loss surgery


Issue Date: 2015-12-03

CHAPTER 2

Impact of obesity on drug metabolism and elimination in adults and children

Margreke J.E. Brill
Jeroen Diepstraten
Anne van Rongen
Simone van Kralingen
John N. van den Anker
Catherijne A.J. Knibbe

Clin Pharmacokinet. 2012; 51(5): 277-304



ABSTRACT

The prevalence of obesity in adults and children is rapidly increasing across the world. Several general (patho)physiological alterations associated with obesity have been described, but the specific impact of these alterations on drug metabolism and elimination and its consequences for drug dosing remains largely unknown.

In order to broaden our knowledge of this area, we have reviewed and summarized clinical studies that reported clearance values of drugs in both obese and non-obese patients. Studies were classified according to their most important metabolic or elimination pathway. This resulted in a structured review of the impact of obesity on metabolic and elimination processes, including phase I metabolism, phase II metabolism, liver blood flow, glomerular filtration and tubular processes.

This literature study shows that the influence of obesity on drug metabolism and elimination greatly differs per specific metabolic or elimination pathway. Clearance of cytochrome P450 (CYP) 3A4 substrates is lower in obese as compared with non-obese patients. In contrast, clearance of drugs primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT), glomerular filtration and/or tubular-mediated mechanisms, xanthine oxidase, *N*-acetyltransferase or CYP2E1 appears higher in obese versus non-obese patients. Additionally, in obese patients, trends indicating higher clearance values were seen for drugs metabolized via CYP1A2, CYP2C9, CYP2C19 and CYP2D6, while studies on high-extraction-ratio drugs showed somewhat inconclusive results. Very limited information is available in obese children, which prevents a direct comparison between data obtained in obese children and obese adults.

Future clinical studies, especially in children, adolescents and morbidly obese individuals, are needed to extend our knowledge in this clinically important area of adult and paediatric clinical pharmacology.

INTRODUCTION

Currently more than 30% of the US population is obese (Body Mass Index (BMI) $>30 \text{ kg/m}^2$)¹⁻², while approximately 5% have been reported to be morbidly obese (BMI $>40 \text{ kg/m}^2$)³. In Europe the prevalence of adult obesity ranges from 9-29% depending on the country⁴ and increases every year. Also for children strong upward trends are observed. According to the national health and nutrition examination survey, conducted in 2007 – 2008, 17% of US children are obese⁵. Upcoming economies, such as China and India, also show an alarming increase of obesity in both adults and children with more than 30% of Chinese adults being overweight⁶. If current trends persist, there will be 2.16 billion overweight and 1.12 billion obese individuals worldwide in 2030 as compared with 388–405 million obese individuals in 2005⁷.

In view of this trend, it is important to understand the impact of obesity on drug metabolism and elimination and its consequences for drug dosing in the (morbidly) obese population. Obesity and morbid obesity are associated with several (patho)physiological changes that may influence the pharmacokinetics of drugs. Among other factors, obese patients have relatively more fat and less lean tissue per kilogram of total body weight than non-obese individuals⁸⁻⁹. Blood volume is observed to be increased, particularly in the morbidly obese¹⁰⁻¹¹. In addition, studies have confirmed that obese patients suffer from low-grade inflammation¹², which is probably the underlying cause of the high prevalence of non-alcoholic steatohepatitis (NASH)¹³⁻¹⁴. NASH has been reported to either increase or decrease drug metabolizing enzyme activity¹⁵⁻¹⁸. The net effect of obesity on drug metabolism is also influenced by cardiac output and liver blood flow, both of which are shown to be increased in obese patients¹⁹. Concerning renal function, a state of glomerular hyperfiltration similar to the condition seen in early-stage diabetic nephropathy and sickle cell disease has been reported in obese individuals²⁰⁻²¹. Until now, the influence of obesity on tubular processes has been unknown.

In summary, many (patho)physiological alterations associated with obesity have been described in the literature, yet the impact of these alterations on specific drug metabolic and elimination pathways has not been clearly summarized. Numerous publications have described obesity-related alterations in all aspects of drug pharmacokinetics, including absorption, distribution, metabolism and elimination of drugs^{9, 22-30}. In addition, several publications have tried to provide practical guidelines for dosing in this population^{9, 23-28}. In recent publications, the influence of obesity on drug metabolism and renal elimination was stated to be inconclusive and inconsistent, with drug clearance being the most important pharmacokinetic parameter for maintenance dosing regimens^{9, 22, 24, 27, 30}. In some cases, results from animal or *in vitro* studies have been used to fill the knowledge gaps^{27, 30}. So far, many pharmacokinetic studies have been performed in obese patients and these studies may represent a wealth of knowledge

on clearance of specific drugs in obesity. In this review our goal was to order and sort pharmacokinetic studies by their primary drug metabolic or elimination pathway to gain insight into how these pathways change with obesity. Therefore, drugs representative for a specific pathway were included in the review, in order to generate knowledge on obesity-related changes in the most important metabolic and elimination pathways in humans. As such, this review provides insight into how obesity affects specific drug metabolism and renal elimination pathways in both obese adults and obese children, on the basis of results of pharmacokinetic studies in obese and non-obese individuals. For this purpose, a direct comparison between drug clearance in obese and non-obese individuals is necessary; therefore, clinical trials that included both obese and non-obese individuals were reviewed in this analysis.

SEARCH STRATEGY AND SELECTION CRITERIA

Approach

We studied individual drug metabolism and elimination processes by using drug clearance values as surrogate markers for these processes. To allow for direct comparisons between obese and non-obese individuals, clinical studies that investigated drug pharmacokinetics in both obese and non-obese patients were collected. The drugs reported in these clinical studies were categorized by their currently known rate-limiting clearance processes, and absolute clearance values were summarized in tables, which is an approach that has been applied before²⁹. In addition, weight-normalized clearance values were added to provide information on the weight-normalized changes in clearance values between non-obese and obese individuals. These weight-normalized clearance values were either directly extracted from the original publication or derived by dividing mean clearance by mean total body weight. As an alternative to total body weight, consideration was given to normalizing clearance values for lean body weight, as this parameter is often proposed as a body size descriptor for obese patients^{27, 31}. Unfortunately, this parameter was reported in only very few studies included in this review; therefore, it was not possible to report clearance values adjusted for lean body weight.

Clearance processes were divided into metabolism and renal elimination. For drug metabolism, phase I metabolism, phase II metabolism and liver blood flow were considered. Drugs for which information about the rate-limiting cytochrome P450 (CYP) process was inconclusive were included in the Other Phase I Metabolism section. For renal elimination, two processes involved in drug elimination by the kidneys were identified: glomerular filtration and tubular processes (tubular secretion and tubular reabsorption).

Inclusion criteria

Papers from the international peer reviewed literature reporting drug pharmacokinetics in obese and normal-weight adults or children were eligible for inclusion. Drugs were included if cleared by a specific metabolic or renal elimination pathway, as reported in international peer reviewed literature. This reference about the drug's main metabolic or elimination route was included in the tables.

Search terms and search results

The PubMed database was used for the search for papers in which the pharmacokinetics of a drug were studied in both an obese and non-obese population. The following search terms were used:

- (Clearance[All Fields] AND ('obesity'[MeSH Terms] OR 'obesity'[All Fields])) AND (controls[All Fields] OR normal[All Fields] OR healthy[All Fields]), yielding 562 results on 2 March 2011.
- '[Substrate]' and 'obesity' and 'pharmacokinetics'. Substrates mentioned in Cytochrome P450 Drug Interaction Table were used ³². A total of 91 (CYP3A4), 10 (CYP2E1), 35 (CYP2D6), 43 (CYP1A2), 23 (CYP2C19), 14 (CYP2C9), 1 (CYP2C8), 7 (CYP2B6) papers of interest were found between March and May 2011.
- '[Kidney process]' and 'obesity' and 'pharmacokinetics'. A total of 18 (glomerular), 5 (tubular secretion) and 2 (tubular reabsorption) papers of interest were found between May and June of 2011.

Additionally, references in the selected articles were checked for additional publications to include in this review.

Exclusion criteria

From studies investigating pharmacokinetics of drugs in both obese and non-obese patients, the following studies were excluded: studies on drugs for which the metabolic or renal elimination pathway was reported to be miscellaneous, unknown or inconsistent, as concluded from peer reviewed literature; studies investigating endogenous substances (including insulin); pharmacodynamic studies; animal studies; case reports; and *in vitro* studies.

DRUG METABOLISM

Drug metabolism predominantly occurs in the liver through enzymes responsible for the modification of functional groups (phase I reactions) and the conjugation of endogenous substituents to drugs to make them even more polar (phase II conjugation) ³³.

In 90% of obese patients, histologically proven liver abnormalities as fatty infiltration are present³⁴. Non-alcoholic fatty liver disease (NAFLD) may range from simple liver steatosis without inflammation to non-alcoholic steatohepatitis (NASH) with active hepatic inflammation. NASH prevalence is difficult to assess, because the diagnosis can only be confirmed using a liver biopsy. However, it is estimated that up to 20% of the obese population and up to 50% of morbidly obese patients have NASH³⁵, and its incidence correlates with BMI (kg/m²)³⁶. While fatty infiltration of the liver may result in altered enzyme activity of phase I or II systems, this enzyme activity may also be subject to changes caused by other obesity-associated (patho)physiological changes such as the chronic state of inflammation^{12, 16}.

To describe the enzyme activity of phase I and II systems in obesity, we provide in this section an overview of clinical studies investigating drugs of which clearance is dependent on phase I or II reactions or liver blood flow and which were studied in both obese adults or children and non-obese adults or children in one report.

Phase I metabolism

Phase I enzymes catalyse the modification of functional groups of a substrate (i.e. oxidation, reduction and hydrolysis), and the majority of these enzymes consist of CYPs. CYPs are predominantly located in the endoplasmatic reticulum of hepatocytes. Other sites include the gastro-intestinal tract, where significant amounts of gene expression of various CYP isoforms have been detected³⁷⁻³⁸. CYP enzyme metabolism contributes to approximately 75% of all drug metabolism³⁹. In this section, we provide an updated review of all studies that have investigated phase I-mediated drug clearance in both obese and non-obese patients in one report.

Cytochrome P450 (CYP) 3A4

CYP3A4 is involved in the phase I metabolism of approximately 50% of all drugs⁴⁰. In table I, an overview of the studies comparing clearance of CYP3A4-metabolized drugs in both obese and non-obese individuals is presented. The pharmacokinetics of ten CYP3A4 substrates in obese versus non-obese subjects have been reported, including alfentanil, midazolam, triazolam, alprazolam, cyclosporine, carbamazepine, docetaxel, taranabant, trazodone and *N*-methyl-erythromycin.

As an *in vivo* probe of CYP3A4 activity, *N*-methyl-erythromycin, midazolam, triazolam, alprazolam and cyclosporine are widely applied⁴¹⁻⁴⁶. In this respect, it was reported that obesity was significantly associated with lower metabolism of [¹⁴C]-*N*-methyl-erythromycin, measured as exhaled ¹⁴CO₂ in both men and women ($r^2 = 0.91$ and $r^2 = 0.90$, respectively)⁴¹⁻⁴², indicating reduced CYP3A4 metabolic activity. Similarly, triazolam clearance was significantly lower in obese patients⁴⁷. For midazolam⁴⁸, alprazolam⁴⁷ and cyclosporine⁴⁹⁻⁵⁰, clearance values were reported to be lower in obese versus non-

obese individuals, though this was not statistically significant, potentially because of the limited power of these studies.

A trend towards lower CYP3A4 activity associated with obesity was also found for other major CYP3A4-cleared drugs. Carbamazepine clearance in non-obese versus obese patients was only marginally higher⁵¹. Upon major weight loss, carbamazepine clearance in six obese patients was significantly increased⁵². As an explanation, it has been suggested that a fatty liver, as observed by abdominal ultrasound, may hinder carbamazepine metabolism either by inhibition of important biochemical reactions or by reduction in liver blood flow. After weight loss, ultrasound images showed a disappearance of fatty changes, in line with an increase in carbamazepine clearance. Clearance of alfentanil, which is also predominantly metabolized by CYP3A4⁵³, was almost halved in obese as compared with non-obese patients⁵⁴. The pharmacokinetics of taranabant, primarily metabolized by CYP3A4⁵⁵, were studied using data from 12 phase 1 clinical trials and one phase 2 study, including 385 obese individuals (BMI range 30-43 kg/m²)⁵⁶. While the authors found a lower estimated oral clearance in obese individuals, they attributed this result to either increased protein binding or a decrease in CYP3A activity.

For two CYP3A4 substrates no difference in clearance was reported in obese versus non-obese patients. Trazodone, for which CYP3A4 is the major isoenzyme involved in the formation of its metabolite⁵⁷⁻⁵⁸, showed no difference in clearance between obese and non-obese patients. Furthermore, docetaxel clearance values of adults patients were not significantly different between non-obese, obese or morbidly obese adults⁵⁹.

In studies of patients before and after gastric bypass surgery an increase in activity of CYP3A4 metabolism in obese individuals was reported. Cyclosporine requirement in patients after gastric bypass surgery was significantly increased from 1.8 to 3.5 mg/kg/d ($p=0.02$), in order to maintain similar cyclosporine trough levels⁶⁰. Similarly it was reported that higher, tacrolimus, sirolimus (CYP3A4⁶¹⁻⁶²) and mycophenolic acid (CYP3A4, CYP2C8⁶³) doses were needed in transplant recipients with a gastric bypass to ensure exposure similar to that in a non-bypass patient⁶⁴. In contrast, atorvastatin bioavailability 3 – 6 weeks after gastric bypass surgery was found to be both increased and decreased as compared with before surgery⁶⁵⁻⁶⁶. The observations made in these gastric bypass studies seem to reflect an increase in CYP3A4-mediated clearance in after weight loss. However, these observations may also be explained by the surgical procedures or an increase in activity of CYP3A4 located in the intestines, both causing reduced absorption of oral drugs. Finally, it could be a combination of the factors mentioned. To our knowledge, no studies have investigated the oral bioavailability of CYP3A4 substrates in obese (gastric bypass) patients versus non-obese patients, and as such, we cannot distinguish between these factors.

In summary, 7 out of 13 studies presented in Table 1 show a significantly lower clearance of CYP3A4 substrates in obese patients and 4 studies show non-significantly lower

Table 1 Cytochrome P450 (CYP) 3A4-mediated clearance in both obese and non-obese patients (pts)

Substrate (reference) ^a	Clearance							Reference	
	Obese pts ^b	Non-obese pts ^b	Dose	Parameter	Obese pts ^b	Non-obese pts ^b	Significance		Weight normalized clearance (obese vs non-obese pts) ^{b,c}
Taranabant ⁵⁵	n = 385 BMI 35.4 (3.8) kg/m ²	n = 187 BMI 25 (3.2) kg/m ²	0.5–8.0 mg PO	CL/F	22.4 (CV 44%) L/h	35.6 (CV 51%) L/h	NA	NA	56
Docetaxel ¹⁷⁶	n = 21 BMI >30 kg/m ²	n = 130 BMI <30 kg/m ²	55–100 mg/m ² IV	CL	BMI 30–35 kg/m ² : 46.1 (15) L/h	40.9 (15) L/h	NS	NA	59
Docetaxel ¹⁷⁶	n = 21 BMI >30 kg/m ²	n = 130 BMI <30 kg/m ²	55–100 mg/m ² IV	CL	BMI >35 kg/m ² : 42.3 (13) L/h	40.9 (15) L/h	NS	NA	59
Carbamazepine ⁴⁵	n = 18 TBW 111.4 (20) kg BMI 38.8 (6.0) kg/m ²	n = 13 TBW 63.2 (8.3) kg BMI 22.4 (1.6) kg/m ²	200 mg PO	CL	19.8 (1.2) mL/min	23.0 (1.3) mL/min	p = 0.07	0.18 vs 0.36 mL/min/kg	51
Carbamazepine ⁴⁵	n = 6 TBW 122 (8.4) kg BMI 42.5 (3.2) kg/m ²	n = 6 ^d TBW 92.2 (4.2) kg BMI 32.0 (1.4) kg/m ²	200 mg PO	CL	20.4 (1.8) mL/min	31.6 (5.0) mL/min	p < 0.05	0.17 vs 0.34 mL/min/kg	52
ERBT ⁴⁴	n = 6 TBW >130% IBW	n = 18 Age 70–88 ^e y	0.074 mmol	[¹⁴ C]N-methyl erythromycin	Negative correlation between %IBW and ERBT		p = 0.001	NA	41
ERBT ⁴⁴	n = 5 TBW >130% IBW	n = 4 (hypertensive pts) Age 45–72 ^e y	0.074 mmol	[¹⁴ C]N-methyl erythromycin	Negative correlation between %IBW and ERBT		p < 0.001	NA	42

Table 1 (continued)

Substrate (reference) ^a	Clearance						Reference vs non-obese pts) ^{bc}	Weight normalized clearance (obese pts) ^{bc}
	Obese pts ^b	Non-obese pts ^b	Dose	Parameter	Obese pts ^b	Non-obese pts ^b	Significance	Weight normalized clearance (obese pts) ^{bc}
Midazolam ⁴⁶	n = 20 TBW 116.5 (7.6) kg	n = 20 TBW 65.7 (1.5) kg	5 mg IV, 10 mg PO	CL	472 (38) mL/min	530 (34) mL/min	NS	4.2 vs 8.1 mL/min/kg
Triazolam ⁴³	n = 12 TBW 111.6 (12) kg	n = 12 TBW 63.8 (2.9) kg	1 mg PO	CL	340 (44) mL/min	531 (38) mL/min	p < 0.025	3.05 vs 8.32 mL/min/kg
Alprazolam ⁴³	n = 12 TBW 111.6 (12) kg	n = 12 TBW 63.8 (2.9) kg	0.5 mg PO	CL	66.4 (7.0) mL/min	88 (9.7) mL/min	NS	0.60 vs 1.38 mL/min/kg
Cyclosporine ⁴³	n = 10 TBW 89.7 (11) kg	n = 35 TBW 62.5 (8.4) kg	2.5 mg/kg IV and 14 mg/kg PO (mg/kg)	CL	700 mL/min	780 mL/min	NS	7.80 vs 12.48 mL/min/kg
Cyclosporine ⁴³	n = 13 TBW 102.6 (4.4) kg (>125% IBW)	n = 38 TBW 67.8 (2.2) kg (≤125% IBW)	2.8 (2.0–3.3) mg/kg IV	CL	Lower CL		NS	CL in obese pts is halved when normalized for weight
Trazodone ^{57,58}	n = 23 112 (7) kg	n = 23 TBW 65 (2) kg	25 mg IV, 50 mg PO	CL	146 (10) mL/min	136 (8) mL/min	NS	1.30 vs 2.09 mL/min/kg
Alfentanil ⁵³	n = 6 TBW 123 kg	n = 7 TBW 64 kg	6838 vs 5990 µg	CL	179 mL/min	321 mL/min	p < 0.01	1.46 vs 5.02 mL/min/kg

a The references mentioned with the substrate (first column) refer to literature in which the appropriateness of the particular drug as a CYP3A4 probe was confirmed.
b Unless otherwise specified, mean values (standard deviation or range).

c Body weight normalized clearance values were either taken from the reference or calculated using the mean clearance and mean body weight of the study group. Also see section Approach for calculation of weight-normalized clearance values.
d Same pts after weight loss.

e Values are expressed as range.

BMI = body mass index; CL = drug clearance; CV = coefficient of variation; ERBT = erythromycin breath test; F = bioavailability; %IBW = percentage of ideal body weight; IV = intravenously; NA = not available; NS = not significant; PO = orally; t_{1/2} = elimination half-life; TBW = total body weight.

absolute clearance values. Body weight-normalized clearance values, as depicted in Table 1, show that drug clearance per kilogram body weight is halved in obese individuals. The underlying mechanism of impaired CYP3A4 metabolism and the potential consequences for CYP3A4 drug-drug interactions in obese patients are unclear and should be subjects of future research. Furthermore, it should be noted that the majority of patients included in these studies were mildly obese, while only a few morbidly obese patients (BMI >40 kg/m²) were included. To date, the pharmacokinetics of CYP3A4-metabolized drugs have not been studied in obese children or adolescents.

CYP2E1

Although CYP2E1 metabolism represents only about 5% of phase I drug metabolism³⁹, the impact of obesity on CYP2E1 activity has been the subject of several studies, in which also a significant proportion of morbidly obese patients were included. Chlorzoxazone, enflurane, sevoflurane and halothane represent the four model drugs for CYP2E1 activity reviewed here, of which the results are summarized in Table 2.

Chlorzoxazone pharmacokinetics were studied in several clinical trials, as this drug is a highly selective probe of CYP2E1 metabolism⁶⁷. In women, it was shown that morbid obesity is associated with increased 6-hydroxylation of chlorzoxazone, which is consistent with induction of CYP2E1⁶⁸. For obese patients, with or without non-insulin-dependent diabetes mellitus, it was found that CYP2E1 activity was 40% higher as compared with non-obese subjects^{67,69}.

More recently, CYP2E1 activity in obesity was further studied by Emery *et al.*¹⁸. Unbound oral clearance (CL_{unbound}/F) of chlorzoxazone was approximately 3-fold higher in morbidly obese compared with non-obese individuals (p<0.001). Six weeks and 1 year post-weight-reducing surgery, chlorzoxazone CL_{unbound}/F in patients was reduced. The authors suggest a causal relationship between the induction of CYP2E1 activity and hepatic fatty infiltration, based on liver biopsy assessment. They found a trend towards higher CL_{unbound}/F with increasing severity of liver fatty infiltration or steatosis (P=0.06). More specifically they showed that CL_{unbound}/F was significantly higher among subjects with steatosis involving >50% of hepatocytes, compared with those with steatosis in ≤ 50% of hepatocytes (p=0.02)¹⁸.

Volatile anesthetics, including enflurane, sevoflurane and halothane, are partly metabolized by CYP2E1. Ionic fluoride is formed by CYP2E1 oxidation of enflurane and sevoflurane, and therefore represents a reliable marker of CYP2E1 metabolism⁷⁰⁻⁷¹. A third volatile anesthetic, halothane, undergoes CYP2E1 biotransformation, which results in trifluoro-acetic acid⁷². After a similar dose of enflurane maximal ionic fluoride concentrations were found to be significantly higher in obese compared with non-obese patients⁷³⁻⁷⁴. A similar result was seen for sevoflurane in obese versus non-obese patients⁷⁵. A second sevoflurane study did not find a significant difference in ionic fluoride concentrations between obese

and non-obese patients⁷⁶. After similar doses of halothane, significantly higher trifluoroacetic acid concentrations in obese patients at 1 and 3 hours after dosing were found⁷⁷.

The studies summarized in Table 2 show a consistent and significant increase in clearance of different CYP2E1 substrates in obese as compared with non-obese subjects, indicating induction of CYP2E1 activity in obesity. When normalized for body weight, clearance values are more or less equal among obese and non-obese individuals, which indicates that CYP2E1 activity increases with body weight. As an explanation, liver fatty infiltration, which is expected to increase with increasing body weight, may be the underlying cause of the CYP2E1 enzyme activity increase with body weight¹⁸. In obese children, no studies on CYP2E1-metabolized drugs have been performed yet.

With regard to the higher CYP2E1 activity observed in obese patients, it can be anticipated that caution should be practiced when using paracetamol (acetaminophen) in obese patients, as CYP2E1 catalyses the formation of the toxic metabolite *N*-acetyl-*p*-benzo-quinone imine (NAPQI). Two studies have looked into paracetamol pharmacokinetics in both obese and non-obese patients⁷⁸⁻⁷⁹. Both studies are discussed in the Phase II metabolism section, because 90% of paracetamol is conjugated via phase II metabolism and only 5–10% of paracetamol is metabolized by CYP2E1⁸⁰. Moreover, one study⁷⁹ did not report metabolites, but only paracetamol clearance values, while the other did not measure NAPQI or the metabolites formed after NAPQI (APAP-C or APAP-M)⁷⁸. Therefore, the above-stated warning may be considered somewhat speculative, and further studies are needed to assess the role of CYP2E1 in paracetamol metabolism and toxicity in both obese adults and children – in particular, given the importance of paracetamol in paediatric therapeutics.

CYP2D6

CYP2D6 metabolism represents about 10-15% of phase I drug metabolism in humans⁴⁰. The activity of this CYP isoform may differ greatly between individuals depending on its genetic polymorphisms⁸¹⁻⁸². Two CYP2D6 substrates, dexfenfluramine and nebivolol, have been subjects of pharmacokinetic studies in obese and non-obese individuals, as shown in Table 3.

For dexfenfluramine metabolism, there was a trend towards higher dexfenfluramine clearance and higher metabolite/parent ratio in obese versus non-obese subjects⁸³. Nebivolol clearance was significantly higher in obese subjects as compared with non-obese individuals⁸⁴. As nebivolol clearance is relatively high (>1L/min), it may be more dependent on liver blood flow than on intrinsic CYP metabolism. However, as the CYP2D6 phenotype has been found to influence the clearance of nebivolol, it was included in this section⁸⁵.

In summary, these few studies indicate trends towards increased CYP2D6-mediated metabolism in obese versus non-obese patients.

Table 2 Cytochrome P450 (CYP) 2E1-mediated clearance in both obese and non-obese patients (pts)

Substrate (reference) ^a	Clearance					Reference			
	Obese pts ^b	Non-obese pts ^b	Dose	Parameter	Obese pts ^b		Non-obese pts ^b	Signifi- cance	Weight normalized clearance (obese vs non-obese pts) ^{b,c}
Chlorzoxazone ⁶⁷	n = 16 TBW 172 (104–273) kg BMI 60 (45–100) kg/ m ²	n = 16 TBW 59 (48–93) kg BMI 21 (18–26) kg/ m ²	750 mg PO	CL _{unbound} /F	27.5 (9–55) L/min	9.9 (3–49) L/min	p < 0.001	0.16 vs 0.17 L/min/ kg	18
Chlorzoxazone ⁶⁷	n = 14 TBW 172 (104–273) kg BMI 59 (45–100) kg/ m ²	n = 14 ^d TBW 145 (95–247) kg BMI 50 (41–98) kg/ m ²	750 mg PO	CL _{unbound} /F	26.8 (9–56) L/min	16.6 (8–45) L/min	p < 0.05	0.16 vs 0.11 L/min/ kg	18
Chlorzoxazone ⁶⁷	n = 14 TBW 172 (104–273) kg BMI 59 (45–100) kg/ m ²	n = 14 ^e TBW 118 (61–208) kg BMI 43 (22–82) kg/ m ²	750 mg PO	CL _{unbound} /F	26.8 (9–56) L/min	19.5 (8–50) L/min	NS	0.16 vs 0.17 L/min/ kg	18
Chlorzoxazone ⁶⁷	n = 17 BMI 39 (1.4) kg/m ²	n = 42 TBW within 20% IBW	500 mg PO	Metabolite/ parent drug ratio	0.38 (0.1)	0.30 (0.2)	NS	NA	67,69
	n = 13 (NIDD pts) BMI 37 (1.5) kg/m ²	n = 42 TBW within 20% IBW	500 mg PO	Metabolite/ parent drug ratio	0.45 (0.2)	0.30 (0.2)	p = 0.007	NA	67, 69
Chlorzoxazone ⁶⁷	n = 9 (women) BMI 35–50 kg/m ² TBW 119 (16) kg	n = 9 (women) BMI 21–30 kg/m ² TBW 72 (11) kg	250 mg PO	CL (parent)				6.2 (1.7) vs 4.2 (0.8) mL/min/kg (p=0.01)	68
				Fractional CL (6-OH metabolite)				4.0 (1.1) vs 2.52 (0.1) mL/min/kg (p=0.006)	68
Enflurane ⁷⁰	n = 26 TBW 128.4 (6.0) kg BMI 46.3 (1.7) kg/m ²	n = 8 TBW 68.1 (1.2) kg BMI 22.9 (2.0) kg/m ² (p > 0.05)	Similar MAC-hr	FL C _{max}	27.8 (2.0) μmol/L	17.0 (3.0) μmol/L	p < 0.01	0.27 vs 0.25 μmol/L/ kg	73

Table 2 (continued)

Substrate (reference) ^a	Clearance						Reference		
	Obese pts ^b	Non-obese pts ^b	Dose	Parameter	Obese pts ^b	Non-obese pts ^b		Signifi- cance	Weight normalized clearance (obese vs non-obese pts) ^{b,c}
Enflurane ⁷⁰	n = 24 TBW 127.6 (6.0) kg BMI 45.9 (1.7) kg/m ²	n = 7 TBW 67.3 (1.2) kg BMI 23.6 (2.0) kg/m ²	Similar MAC-hr	Rate of FL appearance	5.5 μmol/L/h	2.5 μmol/L/h	NA	0.04 vs 0.03 μmol/L/h/kg	73
				Mean FL C _{max}	28.0 (1.9) μmol/L	17.3 (1.3) μmol/L	p < 0.01	0.22 vs 0.26 μmol/L/ kg	74
Sevoflurane ⁷¹	n = 15 TBW 84.8 (2.7) kg BMI 29.3 (0.8) kg/m ²	n = 16 TBW 63.8 (1.5) kg BMI 22.1 (0.4) kg/m ²	Similar MAC-hr (p > 0.05)	All FL concentrations	Higher in obese pts		p < 0.001	NA	75
				Urinary FL excretion	Higher in obese pts (n = 8)		p < 0.001	NA	75
Sevoflurane ⁷¹	n = 13 TBW 114 (8) kg BMI 41 (1) kg/m ²	n = 10 TBW 73 (3) kg BMI 26 (1) kg/m ²	Similar MAC-hr (p > 0.05)	FL C _{max}	49 μmol/L	42 μmol/L	NS	0.43 vs 0.58 μmol/L/ kg	76
Halothane ⁷²	n = 17 TBW 125 (5) kg BMI 45 (1) kg/m ²	n = 8 TBW 59 (5) kg BMI 22 (2) kg/m ²	Similar MAC-hr (p > 0.05)	TFA serum concentration	At T = 1 and 3 h, significantly higher in obese pts		p < 0.05	NA	77

a The references mentioned with the substrate (first column) refer to literature in which the appropriateness of the particular drug as a CYP2E1 probe was confirmed.

b Unless otherwise specified, mean values (standard deviation or range).

c See section Approach for calculation of weight-normalized clearance values.

d 6 wk post-weight-reducing surgery.

e 1 y post-weight-reducing surgery.

f Values are expressed as range.

BMI = body mass index; CL = clearance; CL_{unbound}/F = oral clearance of unbound drug fraction; C_{max} = maximum concentration; FL = ionic fluoride; %BW = percentage of ideal body weight; MAC = minimum alveolar (anaesthetic) concentration; NA = not available; NIDDM = non-insulin-dependent diabetes; NS = not significant; PO = orally; T = time; TBW = total body weight; TFA = trifluoro-acetic acid (metabolite of halothane) ⁷².

Table 3 Cytochrome P450 (CYP) 2D6-mediated clearance in both obese and non-obese patients (pts)

Substrate (reference) ^a	Clearance					Reference
	Obese pts ^b	Non-obese pts ^b	Dose	Obese pts ^b	Non-obese pts ^b	
Dex-fenfluramine ¹⁷⁸	n = 10 BMI 32.2 (2.9) kg/m ²	n = 10 BMI 20.8 (2.0) kg/m ²	30 mg PO	CL 43.9 (21) L/h	CL 37.3 (11) L/h	NS NA 83
Dex-fenfluramine ¹⁷⁸	n = 10 BMI 32.2 (2.9) kg/m ²	n = 10 BMI 20.8 (2.0) kg/m ²	30 mg PO	Parent/ metabolite ratio 2.29 (1.8)	2.05 (1.3)	NS NA 83
Nebivolol ⁸⁵	n = 9 BMI 34.6 (5.6) kg/m ² TBW 99 kg	n = 9 BMI 21.4 (2.6) kg/m ² TBW 60 kg	0.073 mg/kg IBW IV	CL 71.6 (17) L/h	CL 51.6 (11) L/h	p < 0.05 0.72 vs 0.86 L/h/kg 84

a The references mentioned with the substrate (first column) refer to literature in which the appropriateness of the particular drug as a CYP2D6 probe was confirmed.
b Unless otherwise specified, mean values (standard deviation).

c See section Approach for calculation of weight-normalized clearance values.

BMI = body mass index; CL = clearance; IBW = ideal body weight; IV = intravenously; NA = not available; NS = not significant; PO = orally; TBW = total body weight.

CYP1A2

CYP1A2 metabolism represents a small part (~5%) of total phase I drug metabolism. Smoking has an inducing effect on CYP1A2 activity⁸⁶. Caffeine and theophylline have been indicated as CYP1A2-specific probes⁸⁷⁻⁸⁸ and have been studied in obese versus non-obese populations by different research groups (Table 4).

In adults, caffeine clearance was not significantly different between non-smoking obese and non-smoking non-obese patients and between obese patients before and after weight loss⁸⁹. Two earlier caffeine studies in adult obese and non-obese subjects also did not show a significant difference in caffeine clearance⁹⁰⁻⁹¹.

In children aged between 6 and 10 years, Chine *et al.* evaluated oxidative enzyme activity of CYP1A2, using the urinary metabolic ratio of caffeine metabolites⁹². The authors observed non-significantly lower CYP1A2 enzyme activity in obese as compared with non-obese children.

Theophylline clearance showed a significant decrease in 16 obese women after a 6.2 (1.5) kg weight loss⁹³. In a study with 200 individuals, no significant difference in theophylline clearance between moderately obese and non-obese subjects was found⁹⁴. However, after correcting for the influence of smoking, higher total body clearance associated with obesity was found for a select group of young non-smoking subjects ($p < 0.025$). In a third study, it was shown that theophylline clearance correlates with total body weight and not with ideal body weight⁹⁵.

In summary, trends of higher clearance values in obese as compared with non-obese patients indicate a slight increase in CYP1A2 activity. When corrected for body weight, clearance values showed both higher and lower clearance values for obese individuals as compared with non-obese subjects (Table 4).

CYP2C9

CYP2C9-mediated metabolism represents about 10% of phase I drug metabolism in humans. For this review, four CYP2C9 substrates (ibuprofen, phenytoin, glimepiride and glipizide) were identified and are presented in Table 5.

Phenytoin and ibuprofen are widely accepted CYP2C9 substrates⁹⁶⁻⁹⁷. Phenytoin and ibuprofen clearance showed a trend towards higher⁹⁸ and significantly⁹⁹ higher clearance in obese patients, respectively. Non-significantly higher CYP2C9 activity in obese subjects was also seen for glimepiride and glipizide. Glimepiride is metabolized primarily by CYP2C9 to the active M1 hydroxy metabolite, the cyclohexyl hydroxymethyl derivative¹⁰⁰. Glimepiride clearance of the parent drug and of the CYP2C9-dependent metabolite M1 were not significantly different in obese versus non-obese type-2 diabetes patients. However, the cumulative urine excretion of M1 over 24 hours post dose was 30% ($p < 0.05$) higher in obese versus non-obese subjects, while both groups received equal doses¹⁰¹. For glipizide (a CYP2C9 substrate¹⁰²), clearance was slightly higher,

Table 4 Cytochrome P450 (CYP) 1A2-mediated clearance in both obese and non-obese patients (pts)

Substrate (reference) ^a	Clearance						Reference
	Obese pts ^b	Non-obese pts ^b	Dose	Parameter	Obese pts ^b	Non-obese pts ^b	Weight normalized clearance (obese vs non-obese pts) ^{b,c}
Caffeine ⁸⁷	n = 9 (children) age 6–10 ^d y TBW >95th %BMI	n = 16 (children) age 6–10 y TBW <84th %BMI	11.5 mg PO	Metabolic ratio	n = 7 5.4 (2.1)	n = 13 6.7 (1.7)	NA 92
Caffeine ⁸⁷	n = 6 TBW 122 (8.4) kg BMI 42.5 (3.2) kg/m ²	n = 6 ^e TBW 92.2 (4.2) kg BMI 32.0 (1.4) kg/m ²	200 mg PO	CL	113.7 (63) mL/min	135.7 (83) mL/min	0.93 vs 1.47 mL/min/kg 89
Caffeine ⁸⁷	n = 14 TBW 110.4 (19) kg BMI 38.5 (5.8) kg/m ²	n = 14 TBW 66.9 (13) kg BMI 22.6 (1.7) kg/m ²	200 mg PO	CL	88.4 (47) mL/min	82.6 (34) mL/min	0.80 vs 1.23 mL/min/kg 89
Caffeine ⁸⁷	n = 3 TBW 110 (27.5) kg	n = 3 TBW 74.0 (7.8) kg	5.83 mg/kg LBW PO	CL	355 (119) mL/min	219 (45) mL/min	3.23 vs 2.96 mL/min/kg 90
Caffeine ⁸⁷	n = 16 TBW 110 (8) kg	n = 23 TBW 64 (3) kg	162 mg PO	CL	135 (14) mL/min	112 (12) mL/min	1.22 vs 1.75 mL/min/kg 91
Theophylline ⁸⁸	n = 16 (women) TBW 102.8 (21) kg BMI 38.6 (7.8) kg/m ²	n = 16 (women) ^e TBW 6.2 (1.5) kg	250 mg IV	CL	55 (14) mL/min	48 (13) mL/min	0.54 vs 0.50 mL/min/kg 93
Theophylline ⁸⁸	n = 62 TBW 115–155% ^d IBW	n = 133 TBW <115% IBW	Various protocols	CL	62.9 (33) mL/h/kg IBW	55.5 (28) mL/h/kg IBW	NA 94
Theophylline ⁸⁸	n = 5 TBW >155% IBW	n = 133 TBW <115% IBW	Various protocols	CL	59.7 (21) mL/h/kg IBW	55.5 (28) mL/h/kg IBW	NA 94

a The references mentioned with the substrate (first column) refer to literature in which the appropriateness of the particular drug as a CYP1A2 probe was confirmed.

b Unless otherwise specified, mean values (standard deviation or range).

c See section Approach for calculation of weight-normalized clearance values.

d Values are expressed as range.

e Same pts after weight loss.

BMI = body mass index; CL = clearance; IBW = ideal body weight; %IBW = percentage of IBW; IV = intravenously; LBW = lean body weight; NA = not available; NS = not significant; PO = orally; TBW = total body weight.

which was not statistically different in obese as compared with non-obese subjects, though the difference in body weight was rather limited¹⁰³.

In summary, these studies indicate slightly increased CYP2C9-mediated clearance in obese as compared with non-obese patients. Body weight-normalized clearance values show a slight decrease in CYP2C9-mediated clearance per kilogram of total body weight (Table 5).

CYP2C19

CYP2C19 biotransformation is involved in approximately 5% of all phase I drug metabolism. As for CYP2D6 and CYP2C9, the activity of this isoform may largely differ depending on genetic polymorphisms¹⁰⁴. Only one clinical study, which is presented in Table 6, investigated the pharmacokinetics of CYP2C19 probes, i.e. diazepam and methyl diazepam¹⁰⁴⁻¹⁰⁵. Diazepam clearance was higher in the obese group, and no difference in desmethyl diazepam clearance in obese versus non-obese individuals was found¹⁰⁶⁻¹⁰⁷. Body weight-normalized clearance values show a slight decrease in CYP2C19-mediated clearance for obese individuals (Table 6).

Other phase I metabolic enzymes

Xanthine oxidase

Besides CYP enzymatic pathways, there is a wide variety of other enzymes contributing to phase I metabolism of drugs. However, often no appropriate substrate for a particular enzyme has been identified¹⁰⁸. We have identified two studies in children, investigating the pharmacokinetics of the xanthine oxidase-metabolized compounds mercaptopurine and caffeine (Table 7).

Mercaptopurine undergoes extensive biotransformation by xanthine oxidase¹⁰⁹. In children, mercaptopurine clearance values were found to be higher in overweight or obese children as compared with non-obese children. In addition, a significant correlation between drug exposure and fat body mass, expressed by the weight/height percentile, was demonstrated¹¹⁰.

Xanthine oxidase also mediates the biotransformation of the caffeine metabolite 1-methylxanthine into 1-methyluric acid, which can be measured in urine. The metabolic ratio for xanthine oxidase, measured using the metabolites in urine, was higher in obese children than in non-obese children between 6 and 10 years of age⁹². Obese children also showed elevated interleukin-6, C-reactive protein, and leptin levels, whereas adiponectin levels were decreased as compared with the non-obese children⁹². It was suggested that these pro-inflammatory cytokines and adipokines upregulate xanthine oxidase gene expression and activity. Another explanation for the increase in xanthine oxidase activity may be the increase in liver volume associated with obesity.

Table 5 Comparison of cytochrome P450 (CYP) 2C9-mediated clearance between obese and non-obese patients (pts).

Substrate (reference) ^a	Clearance					Signifi- cance	Weight normalized clearance (obese vs non-obese pts) ^{b,c}	Reference
	Obese pts ^b	Non-obese pts ^b	Dose	Obese pts ^b	Non-obese pts ^b			
Glimepiride ¹⁰⁰	n=14 T2D, 130 (36) kg	n=14 T2D 72.0 (10) kg	8 mg p.o.	Normalized CL 2.1 (0.1) L/h/1.73 m ²	2.1 (0.8) L/h/1.73 m ²	NS	NA	101
			8 mg p.o.	Cumulative M1 in 24h urine 130%	100%	P=0.043	NA	
Glipizide ¹⁰²	n=12 95.5 (17) kg	n=8 80.8 (10) kg	5 mg p.o.	CL 2.3 (1.0) L/h	2.0 (1.0) L/h	NS	0.024 vs 0.025 L/h/kg	103
Ibuprofen ¹⁷⁹	n=11 114 (11) kg 38.6 (3.3) kg/m ²	n=11 61 (3) kg 20.7 (0.5) kg/m ²	600 mg p.o.	CL 83 (4) mL/ min	59 (4) mL/ min	P<0.005	0.73 vs 0.97 mL/min/kg	99
Phenytoin ¹⁸⁰	n=14 124 kg 178% IBW	n=10 67 kg 92% IBW	300 mg i.v.	CLmetabolic 59 (10) mL/ min	39 (3) mL/ min	NS	0.48 vs 0.58 mL/ min/kg	98

^a The references mentioned with the substrate (first column) refer to literature in which the appropriateness of the particular drug as a CYP2C9 probe was confirmed.
^b Unless otherwise specified, mean values (standard deviation or range).

^c See section Approach for calculation of weight-normalized clearance values.

BMI = body mass index; CL = clearance; %IBW = percentage of ideal body weight; IV = intravenously; M1 = M1 metabolite of glimepiride, cyclohexyl hydroxymethyl derivative; NA = not available; NS = not significant; PO = orally; T2DM = type 2 diabetes mellitus; TBW = total body weight.

Table 6 Cytochrome P450 (CYP) 2C19-mediated clearance in both obese and non-obese patients (pts)

Substrate (reference) ^a	Clearance					Reference
	Obese pts ^b	Non-obese pts ^b	Dose	Parameter	Weight normalized clearance (obese vs non-obese pts) ^{b,c}	
Diazepam ¹⁰⁵	n=17 101.1 (68-197) kg	n=17 60.4 (49-80) kg	7.5-15 mg i.v.	CL	Obese pts ^b 38.1 (20-80) mL/min Non-obese pts ^b 27.3 (20-51) mL/min Signifi- cance P<0.025	106
Desmethyl- diazepam ¹⁰⁵	n=12 105 (77-197) kg	n=12 67 (51-91) kg	10.3 mg p.o.	CL	Obese pts ^b 13.2 (7-18) mL/min Non-obese pts ^b 13.4 (6-22) mL/min Signifi- cance NS	107

a The references mentioned with the substrate (first column) refer to literature in which the appropriateness of the particular drug as a CYP2C19 probe was confirmed.
b Unless otherwise specified, mean values (standard deviation or range).

c See section Approach for calculation of weight-normalized clearance values.

CL = clearance; IV = intravenously; NS = not significant; PO = orally; TBW = total body weight.

Table 7 Other phase I (xanthine oxidase [XO])–mediated clearance in both obese and non-obese patients (pts)

Substrate (reference) ^a	Clearance						Reference		
	Obese pts ^b	Non-obese pts ^b	Dose	Parameter	Obese pts ^b	Non-obese pts ^b		Signifi- cance	Weight normalized clearance (obese vs non-obese pts)
Caffeine ⁸⁷	n = 9 (children) age 6–10 ^c y TBW >95th %BMI	n = 16 (children) age 6–10 ^c y TBW <84th %BMI	11.5 mg PO	Metabolic ratio of XO	n = 8 0.7 (0.06)	n = 16 0.6 (0.05)	p < 0.001	NA	92
6-mercaptopurine ⁶⁹	n = 9 (children) Age 4–14 ^c y TBW >75th %BMI	n = 9 (children) Age 5–11 ^c y TBW <75th %BMI	Similar doses	CL	206.9 (85) L/h	93.4 (30) L/h	p < 0.001	NA	110

a The references mentioned with the substrate (first column) refer to literature in which the appropriateness of the particular drug as an XO probe was confirmed.
b Unless otherwise specified, mean values (standard deviation or range).

c Values are expressed as range.

BMI = body mass index; %BMI = BMI percentile (used in children); CL = clearance; NA = not available; PO = orally; TBW = total body weight; XO = xanthine oxidase.

In conclusion, xanthine oxidase-mediated clearance was significantly increased in obese versus non-obese children in both studies. To our knowledge, no studies on xanthine oxidase in adults have been performed.

Miscellaneous phase I metabolism enzymes

In addition to typical substrates for phase I drug metabolic enzymes, there are many other drugs that undergo hepatic biotransformation by a combination of phase I and phase II enzymes. As a result, even when the exact share of each involved enzyme is known, it is difficult to predict into what extent drug clearance will be affected in obese adults and children. In Table 8 we have summarized all studies in obese and non-obese patients that have investigated the pharmacokinetics of drugs in which multiple enzymes are involved. Here we will only discuss antipyrine, while for the outcomes of other drugs, we refer to Table 8.

Antipyrine (phenazone) is widely used as a model drug in the assessment of hepatic oxidative capacity in humans, as more than 99% of a given dose is excreted into urine as metabolites. The major metabolic routes are *N*-demethylation to norphenazone (CYP2C8, -2C9, -2C18, -1A2), 4-hydroxylation (CYP3A4, -1A2, -2B6) and 3-methylhydroxylation (CYP1A2, -2C9), which together account for 50% – 80% of the dose¹¹¹. Two antipyrine studies reviewed here did not find significantly different clearance values between the obese and non-obese patient groups^{106, 112}.

The outcomes of the antipyrine studies are representative for the general conclusion from the studies in Table 8. In summary, 8 out of 13 studies did not show significantly different clearance values in obese versus non-obese subjects. Of the 5 studies that did find a difference in clearance values, obese clearance values were either higher (doxorubicin, ethinyl-estradiol and bisoprolol¹¹³⁻¹¹⁵) or lower (amiodarone and doxorubicinol¹¹⁶⁻¹¹⁷) as compared with clearance values in the non-obese group. Per kilogram of body weight, all clearance values were lower in obese as compared with non-obese individuals. The limited influence of obesity on these particular clearance values may in part be explained by compensating mechanisms among the different enzymatic pathways involved. However, it should be noted that the differences in body weight between the obese and non-obese subjects in all of the studies in Table 8 are relatively small. As this is a mixed group of drugs, it is difficult to generalize the results.

Summary of phase I metabolism

In summary, phase I enzymatic processes showed higher, lower or similar activity in obese as compared with non-obese subjects, depending on the enzymatic pathway. CYP3A4 mediated clearance was consistently lower, while CYP2E1-mediated clearance showed higher activity among obese versus non-obese adults. For CYP2E1, it has been demonstrated that an increase of CYP2E1-mediated clearance is correlated with both

total body weight and the degree of liver steatosis, supporting the concept that liver fibrosis and inflammation associated with the increase in body weight are the underlying cause of increased CYP2E1 enzyme activity.

Clearance mediated by phase I metabolizing enzymes (CYP1A2, CYP2C9, CYP2C19 and CYP2D6) showed trends of higher clearance values in obese versus non-obese subjects, although in the majority of studies, this was not statistically significant, and the number of studies was limited. In contrast, CYP1A2 activity in children was non-significantly lower in obese versus non-obese children. Xanthine oxidase activity was significantly higher in obese as compared with non-obese children. Overall, the differences in body weight between obese and non-obese individuals were relatively small, and few or no morbidly obese patients were included in these studies.

Phase II metabolism

Phase II metabolic processes include glucuronide-, *N*-acetyl-, methyl-, glutathione- and sulfate- conjugation of substrates. Uridine diphosphate-glucuronosyltransferase (UGT) enzymes catalyze the conjugation of various endogenous substances and exogenous compounds, and are by far the most important phase II processes for metabolism of drugs (~50%)⁴⁰.

Uridine Diphosphate Glucuronosyltransferase (UGT)

The human UGT superfamily is comprised two families (UGT1 and UGT2) and three sub-families (UGT1A, UGT2A, and UGT2B). Many of the individual UGT enzymes are expressed not only in the liver but also in extrahepatic tissues, including the gastrointestinal tract, adipose tissue and kidneys, where the extent of glucuronidation can be substantial¹¹⁸. As the liver is the main UGT enzyme organ, it is suggested that liver disease or increased organ size, often co-occurring with obesity, is somehow correlated with UGT activity. The expression of specific UGT enzymes in visceral and subcutaneous adipose tissue may also provide an explanation for increased UGT activity in obesity¹¹⁹.

Here we will discuss studies of four drugs that primarily undergo UGT conjugation, i.e. paracetamol, garenoxacin, oxazepam and lorazepam. The studies are summarized in Table 9. In contrast to CYP isoforms, individual UGT enzymes responsible for specific drug biotransformation processes were mentioned in an additional column of Table 9.

Paracetamol is extensively metabolized by UGT enzymes¹²⁰⁻¹²¹. In both adult men and women, significantly higher clearance values were found in obese compared with non-obese individuals⁷⁹. Between adolescents with and without NAFLD, no difference in total body weight-normalized clearance was found, indicating higher absolute clearance values in obese adolescents⁷⁸. Furthermore, the ratio of paracetamol/paracetamol-glucuronide metabolite in urine was significantly increased in obese adolescents, indicating increased UGT metabolism.

Table 8 A combination of phase I- and phase II-mediated clearance in both obese and non-obese patients (pts)

Clearance											
	Substrate (reference) ^a	Metabolic enzymes	Non-obese		Dose	Parameter	Obese pts ^b	Non-obese pts ^b	Signifi- cance	Weight normalized clearance (obese vs non-obese pts) ^{b,c}	Reference
	Voriconazole ¹⁸¹	CYP2C19, 3A4, 2C9	Obese pts ^b	Non-obese pts ^b	200 mg	CL/F	13.4 (8.5–21) L/h	20.0 (14–26) L/h	NS	0.10 vs 0.26 L/h/kg	182
			n = 8 TBW 133 (105–155) kg BMI 46.2 (38–54) kg/ m ²	n = 14 TBW 76.9 (7.1) kg BMI 23.7 (1.9) kg/m ²							
			Obese pts ^b	Non-obese pts ^b	300 mg	CL/F	10.1 (6.8–44) L/h	8.4 (3.9–13) L/h	NS	0.08 vs 0.11 L/h/kg	182
			n = 8 TBW 133 (105–155) kg BMI 46.2 (38–54) kg/ m ²	n = 14 TBW 76.9 (7.1) kg BMI 23.7 (1.9) kg/m ²							
	ethynil estradiol ^{183,185}	CYP3A4, 1A2; UGT1A1c, 2C19	Obese pts ^b	Non-obese pts ^b	30 µg PO	AUC ₂₄	1077 (750–1550) pg • h/mL	1414 (1040– 1920) pg • h/mL	p = 0.04	NA	114
			n = 15 BMI 33.5 (range 31–36) kg/ m ²	n = 13 BMI 22.4 (range 21–24) kg/m ²							
			C _{min}				31.5 (21–47) pg/mL at 24 h	34.2 (24–50) pg/ mL at 24 h	NS	NA	

Table 8 (continued)

Substrate (reference) ^a	Metabolic enzymes	Clearance					Reference			
		Obese pts ^b	Non-obese pts ^b	Dose	Parameter	Obese pts ^b		Non-obese pts ^b	Signifi- cance	Weight normalized clearance (obese vs non-obese pts) ^{b,c}
Levonorg- estrel ^{186,187}	CYP3A4; minor: CYP2E1, 2C19, 2C9	n = 15 BMI 33.5 (range 31–36) kg/ m ²	n = 13 BMI 22.4 (range 21–24) kg/m ²	150 µg PO	AUC	85.8 (62–119) ng • mL/mL	79.9 (45–142) ng • mL/mL	NS	NA	114
					C _{min}	2.6 (1.5–4.5) ng/mL at 24 h	2.5 (1.5–4.0) ng/ mL at 24 h	NS	NA	
Amiodarone ¹⁸⁸	CYP3A4, 2C8	Total n = 23 BMI (obese pts) 25–31.4 kg/m ²	Total n = 23 BMI (non- obese pts) <25 kg/m ²	2.34 (0.68) mg/kg/d	CL		Decrease of 22.3% when BMI >25	p < 0.005	NA	116
Ifosfamide ¹⁸⁹	CYP3A, 2B	n = 4 TBW 76.8 (70.0–86.0) kg	n = 12 TBW 64.2 (48–77) kg	1.5 g/ m ² IV	CL	76.0 (65–92) mL/min	72.2 (53–189) mL/min	NS	0.99 vs 1.14 L/h/kg	190
Antipyrine ^{111, 191}	CYP1A2, 2B6, 2C8, 2C9, 2C18, 3A4	n = 20 TBW 110.4 (19) kg BMI 38.5 (5.8) kg/m ²	n = 11 TBW 62.7 (8.7) kg BMI 22.3 (1.7) kg/m ²	1 g PO	CL	39.3 (12) L/h	34.5 (7.0) L/h	NS	0.36 vs 0.55 L/h/kg	112

Table 8 (continued)

Clearance										
Substrate (reference) ^a	Metabolic enzymes	Obese pts ^b	Non-obese pts ^b	Dose	Parameter	Obese pts ^b	Non-obese pts ^b	Significance	Weight normalized clearance (obese vs non-obese pts) ^{b,c}	Reference
Antipyrine ^{111, 191}	CYP1A2, 2B6, 2C8, 2C9, 2C18, 3A4	n = 6 TBW 122.2 (21) kg BMI 42.5 (7.8) kg/m ²	n = 6 ^e TBW 92.3 (9.1) kg BMI 32.1 (3.0) kg/m ²	1 g PO	CL	41.1 (12) L/min	47.7 (17) L/min	NS	0.34 vs 0.52 L/min/kg	
Antipyrine ^{111, 191}	CYP1A2, 2B6, 2C8, 2C9, 2C18, 3A4	n = 23 TBW 100.3 (59–197) kg	n = 25 TBW 62.5 (49–81) kg	20 mg/kg; maximum 2.0 g IV	CL	38.0 (21–72) mL/min	47.6 (18–103) mL/min	NS	0.38 vs 0.76 mL/min/kg	106
Bisoprolol ¹⁹²	CYP3A4, 2D6	n = 8 (women) TBW 91 (17) kg	n = 8 (women) TBW 51 (4) kg	Similar doses IV	CL	14.8 (1.4) L/h	12.8 (2.2) L/h	p < 0.05	0.163 vs 0.251 L/h/kg	113
Quinine ¹⁹³	CYP3A4, 2D6	n = 9 (Thai pts) TBW 96 (16) kg	n = 8 (Thai pts) TBW 57 (5) kg	600 mg PO	CL	85 (18) L/h	98 (33) L/h	NS	0.89 vs 1.72 L/h/kg	194
Glyburide ¹⁹⁵	CYP3A4, 2C9	n = 12 TBW 100.0 (23) kg BMI 36.0 (9.1) kg/m ²	n = 8 TBW 73.3 (7.2) kg BMI 24.5 (2.0) kg/m ²	20 mg daily dose PO	CL	3.26 (2.2) L/h	3.10 (2.0) L/h	NS	0.03 vs 0.04 L/h/kg	196

Table 8 (continued)

Clearance							
	Parameter	Obese pts ^b	Non-obese pts ^b	Signifi- cance	Weight normalized clearance (obese vs non-obese pts) ^{b,c}	Reference	
Substrate (reference) ^a	Metabolic enzymes	Obese pts ^b	Non-obese pts ^b	Dose			
Doxorubicin ¹⁹⁷	Various, including CYP3A4	n = 22 BMI >30 kg/m ²	n = 77 BMI <30 kg/m ²	40–75 mg/m ² IV	CL	BMI 30–35 kg/m ² (15 pts): 65.7 (17) L/h BMI >35 kg/ m ² (7 pts): 78.9 (27) L/h	p = 0.045 NA R115
Doxorubicin ¹⁹⁷	Various, including CYP3A4	n = 6 (children) age 1–21 ^d y TBW 61.4 kg BMI >30% body fat	n = 16 (children) age 1–21 ^d y TBW 39.6 kg BMI <30% body fat	Based on BSA	Doxorubicin CL	24.6 (2.5) L/h/ m ² 26.0 (6.0) L/h/m ²	NS NA 117
					Doxorubicinol CL	37.2 (15) L/h/ m ² 64.8 (35) L/h/m ²	p = 0.033 NA 117

a The references mentioned with the substrate (first column) refer to literature in which the metabolic enzymes involved in the clearance of the drug are proposed.

b Unless otherwise specified, mean values (standard deviation or range).

c See section Approach for calculation of weight-normalized clearance values.

d Values are expressed as range.

e Same pts after weight loss.

AUC = area under the concentration-time curve; AUC_{0–24} = AUC from 0 to 24 h; BSA = body surface area; CL = clearance; CL/F = oral clearance; C_{min} = minimum concentration; CYP = cytochrome P450; IV = intravenously; M1 = M1 metabolite of glimepiride, cyclohexyl hydroxymethyl derivative; NA = not available; NS = not significant; PO = orally; T2D = type 2 diabetes; UGT = uridine diphosphate glucuronosyltransferase.

Table 9 Uridine diphosphate glucuronosyltransferase (UGT)-mediated clearance in both obese and non-obese patients (pts)

Substrate (reference) ^a	Metabolic enzymes	Clearance							
		Obese pts ^b	Non-obese pts ^b	Dose	Parameter	Obese pts ^b	Non-obese pts ^b	Significance	Weight normalized clearance (obese vs non-obese pts) ^{bc}
Paracetamol ¹²¹	UGT 1A9, 1A6, 2B15	n = 12 (NAFLD children) age 10–17 ^d y BMI 34.0 (6.1) kg/m ²	n = 12 (children) age 10–17 ^d y BMI 26.2 (11) kg/m ²	5 mg/kg up to 325 mg	Metabolite/parent drug ratio	Increased in obese pts		p = 0.028	NA
Paracetamol ¹²¹	UGT 1A9, 1A6, 2B15	n = 12 (NAFLD children) BMI 34.0 (6.1) kg/m ²	n = 12 (children) BMI 26.2 (11) kg/m ²	5 mg/kg up to 325 mg	CL				0.31 vs 0.31 L/kg/h (NS)
Paracetamol ¹²¹	UGT 1A9, 1A6, 2B15	n = 7 (men) TBW 135 kg	n = 10 (men) TBW 71 kg	650 mg IV over 5 min	CL	484 mL/min	323 mL/min	p < 0.05	3.59 vs 4.55 mL/min/kg
Paracetamol ¹²¹	UGT 1A9, 1A6, 2B15	n = 14 (women) TBW 88 kg	n = 11 (women) TBW 55 kg	650 mg IV over 5 min	CL	312 mL/min	227 mL/min	p < 0.05	3.55 vs 4.13 mL/min/kg
Garenoxacin ¹²²	Sulfate conjugation of UGT	n = 196 TBW >130% IBW	n = 384 TBW <130% IBW	Various protocols	CL	Obesity (>130% IBW) was a covariate on CL		p < 0.00001	NA
Oxazepam ¹²⁰	UGT 1A9, 2B7, 2B15	n = 11 TBW 115 (13) kg	n = 11 TBW 60 (2.6) kg	30 mg PO	CL	156.8 (23) mL/min	50.4 (6.0) mL/min	p < 0.001	1.39 vs 0.82 mL/min/kg (p < 0.005)
Lorazepam ¹²⁵	Various, including UGT 2B15	n = 14 TBW 111.7 (10) kg	n = 14 TBW 62.8 (2.2) kg	2 mg IV	CL	102 (10) mL/min	62.9 (5.4) mL/min	p < 0.005	0.98 vs 1.00 mL/min/kg

^a The references mentioned with the substrate (first column) refer to literature in which the appropriateness of the particular drug as an UGT probe was confirmed.

^b Unless otherwise specified, mean values (standard deviation).

^c See section Approach for calculation of weight-normalized clearance values.

^d Values are expressed as range.

BMI = body mass index; BSA = body surface area; CL = clearance; C_{min} = minimum concentration; %IBW = percentage of ideal body weight; IV = intravenously; NA = not available; NAFLD = non-alcoholic fatty liver disease; NS = not significant; PO = orally; TBW = total body weight.

In a population pharmacokinetic analysis of garenoxacin (a major UGT substrate ¹²²), it was found that clearance values increased with total body weight. In the final pharmacokinetic model, an obesity factor (>130% ideal body weight) used as a covariate for clearance significantly improved the model ¹²³.

For both oxazepam and lorazepam, it was found that clearance values were significantly higher in obese as compared with non-obese control subjects ¹²⁴. A determinant role of UGT in the metabolism of both compounds has been shown in the literature ^{120, 125}. On the basis of the differences in oxazepam and lorazepam clearance values, the authors concluded that obesity is associated with an increased conjugating capacity and that this increase is in proportion to total body weight. It should be noted that many subjects in this study received more than one study drug, which may limit the interpretation of these results.

In conclusion, all studies show a significantly increased clearance in obese as compared with non-obese subjects. As a consequence, body weight-normalized clearance values were equal or only slightly lower for obese as compared with non-obese individuals, except for oxazepam clearance, which showed a significant increase in body weight-normalized clearance.

Other metabolic phase II routes

Apart from UGT, the pharmacokinetics of *N*-acetyltransferase (~5% of phase II drug metabolism) and glutathione *S*-transferase-metabolized drugs have been investigated in obese versus non-obese subjects. Caffeine, procainamide and busulfan have been indicated as substrates, as presented in Table 10.

N-acetyltransferase is responsible for the *N*-acetylation of procainamide ¹²⁶. Procainamide plasma clearance was slightly higher in obese as compared with non-obese adults, although this was non-significant ¹²⁷. In obese children, a 5-fold increase in the metabolic ratio of the *N*-acetyltransferase pathway of caffeine was observed when compared with non-obese children ⁹², when only considering the slow-acetylator genotype.

For busulfan, both obese (BMI between 27 and 35 kg/m²) and severely obese patients (BMI > 35 kg/m²) showed significantly higher oral clearance values as compared with non-obese patients ¹²⁸. Per kilogram of body weight, clearance was significantly lower in obese versus non-obese patients. This was confirmed in a more recent trial with busulfan in obese and non-obese adults ¹²⁹. While CYP3A4 involvement is suggested ¹³⁰, the glutathione *S*-transferase A1-1 isoform is the major and possibly determinant pathway of busulfan metabolism ¹³¹. In obese children (aged 0 – 21 years) busulfan clearance per kilogram of body weight after a test dose and a regular dose was lower than in non-obese children ¹³².

In conclusion, other type phase II-metabolized substrates show higher absolute clearance values in obese as compared with non-obese adults and children, while weight-normalized clearance values were lower in obese as compared with non-obese patients.

Table 10 Other phase II-mediated clearance in both obese and non-obese patients (pts)

Clearance										
Substrate (reference) ^a	Metabolic enzymes	Obese pts ^b	Non-obese pts ^b	Dose	Parameter	Obese pts ^b	Non-obese pts ^b	Significance	Weight normalized clearance (obese vs non-obese pts) ^{b,c}	Reference
Caffeine ⁸⁷	NAT2	n = 9 (children) age 6–10 ^c y TBW >95% BMI	n = 16 (children) age 6–10 ^c y TBW <84% BMI	11.5 mg PO	Metabolic ratio of NAT2	n = 6 1.01 (0.3)	n = 14 0.18 (0.1)	p < 0.01	NA	92
Procainamide ^{92,126,178}	NAT2	n = 7 TBW 100.2 (17.3) kg	n = 7 TBW 68.4 (11.5) kg	300 mg IV	CL _{plasma}	51.7 (9.2) L/h	41.9 (14) L/h	p = 0.085	0.52 vs 0.61 L/h/kg	127
Busulfan ¹³¹	GSTA1	n = 22 (children) age 0–21 ^d y TBW >85% BMI	n = 29 (children) age 0–21 ^d y TBW 25–85% BMI	Test dose 0.8 mg/kg IV	CL				3.2 vs 3.8 mL/min/kg (p = 0.1)	132
Busulfan ¹³¹	GSTA1	n = 22 (children) age 0–21 ^d y TBW >85% BMI	n = 29 (children) age 0–21 ^d y TBW 25–85% BMI	2.9 vs 4.0 mg/kg IV	CL				3.1 vs 3.8 mL/min/kg (p = 0.03)	132
Busulfan ¹³¹	GSTA1	n = 39 BMI 27–35 kg/m ²	n = 71 BMI 18–26.9 ^d kg/m ²	0.8 mg/kg IBW, TBW or AIBW IV	CL				2.33 vs 2.63 mL/min/kg (p < 0.05)	129
Busulfan ¹³¹	GSTA1	n = 11 BMI >35 kg/m ²	n = 71 BMI 18–26.9 ^d kg/m ²	0.8 mg/kg IBW, TBW or AIBW IV	CL				1.88 vs 2.63 mL/min/kg (p < 0.05)	129
Busulfan ¹³¹	GSTA1	n = 89 BMI 27–35 ^d kg/m ²	n = 173 BMI 18–27 ^d kg/m ²	0.4–1.8 mg/kg PO	CL/F	223 (53) mL/min	190 (45) mL/min	p < 0.001	2.56 vs 2.90 mL/min/kg (p < 0.01)	128
Busulfan ¹³¹	GSTA1	n = 10 BMI >35 kg/m ²	n = 173 BMI 18–27 ^d kg/m ²	0.4–1.8 mg/kg PO	CL/F	250 (47) mL/min	190 (45) mL/min	p = 0.001	2.30 vs 2.90 mL/min/kg (p < 0.01)	128

a The references mentioned with the substrate (first column) refer to literature in which the appropriateness of the particular drug as a NAT2 or GSTA1 probe was confirmed.

b Unless otherwise specified, mean values (standard deviation).

c See section Approach for calculation of weight-normalized clearance values.

d Values are expressed as range.

AIBW = adjusted ideal body weight; BMI = body mass index; %BMI = BMI percentile (used in children); CL = clearance; CL/F = oral clearance; GSTA1 = glutathione S-transferase A1; IBW = ideal body weight; IV = intravenously; NA = not available; NAFLD = non-alcoholic liver fatty disease; NAT2 = arylamine *N*-acetyltransferase type 2; PO = orally; TBW = total body weight.

Summary of phase II metabolism

For glucuronidation processes, all studies in Table 9 show a significant increase in UGT biotransformation in obese as compared with non-obese subjects. Weight-normalized UGT clearance values were equal to or only slightly lower in obese as compared with non-obese patients. However, the number of studies with UGT-metabolized drugs is small. The underlying mechanism of this phenomenon remains unsolved, although NAFLD was demonstrated to be associated with higher paracetamol clearance values in adolescents ⁷⁸.

N-Acetylation catalyzed by *N*-acetyltransferase shows a significant increase in obese children and a non-significant increase in adults. Glutathione transferase of busulfan in obese children and adults was lower in non-obese adults and children when normalized for body weight.

Liver blood flow

High-extraction-ratio drugs are rapidly metabolized and therefore sensitive to changes in liver blood flow, but are relatively insensitive to changes in enzyme activity and are thus a potential marker of liver blood flow. The influence of obesity on liver blood flow is not fully specified. NASH increases fat deposition in the liver, causing sinusoidal narrowing and altered functional morphology of the liver ¹³³. In contrast, because of increased blood volume and cardiac output, liver blood flow is not necessarily reduced in obese subjects ¹⁹.

In Table 11, studies of eight high extraction ratio drugs in obese and non-obese subjects are summarized and include propofol, propranolol, labetalol, verapamil, lidocaine, fentanyl, sufentanil and paclitaxel.

Propofol is extensively metabolized by various UGT enzymes ¹¹⁸ and its clearance is limited by liver blood flow ¹³⁴. Van Kralingen *et al.* ¹³⁵ and Cortinez *et al.* ¹³⁶ studied propofol pharmacokinetics in a wide range of body weights and found that total body weight as a covariate for clearance significantly improved the predictive performance of the population pharmacokinetic model.

Four different studies reported propranolol clearance values in obese versus non-obese patients. Three studies did not show altered clearance values between obese and

Table 11 Liver blood flow-mediated clearance in both obese and non-obese patients (pts)

Substrate (reference) ^a	Clearance					Weight normalized clearance (obese vs non-obese pts) ^{b,c}	Refer- ence	
	Parameter	Obese pts ^b	Non-obese pts ^b	Dose	Obese pts ^b			
Propofol ¹³⁴	n = 20 BMI 43 (6) kg/m ² TBW 124 (20) kg	n = 44 BMI 25 (4) kg/m ² TBW 74 (11) kg	Continuous infusion	CL	Individual clearance (L/min)= 2.22 • (70/ TBW) ^{0.71}	At 70 kg: 2.22 L/min	p < 0.005	135
Propofol ¹³⁴	n = 27 TBW 82–169 ^d kg	n = 24 TBW 44–122 ^d kg	Continuous infusion	CL	Individual clearance (L/min)= 2.25 • (70/ TBW) ^{0.75}	At 70 kg: 2.25 L/min	p < 0.01	136
Paclitaxel ¹⁹⁸	n = 14 BMI >30 kg/m ²	n = 38 BMI <30 kg/m ²	50–225 mg/ m ²	CL	383 (340–431) L/h	318 (291–347) L/h	NS	59
Sufentanil ¹⁴⁵⁻¹⁴⁶	n = 8 TBW 94.1 (14) kg	n = 8 TBW 70.1 (13) kg	4 µg/kg TBW IV	CL	1.99 (0.9) L/min	1.78 (0.5) L/min	NS	148
Propranolol ¹⁹⁹	n = 9 (normolipidaemic pts) BMI 35.6 (1.2) kg/m ²	n = 18 BMI 24.0 (0.6) kg/ m ²	80 mg PO	CL/F	66.2 (22) L/h	73.1 (16) L/h	NS	137
Propranolol ¹⁹⁹	n = 16 (hyperlipidaemic pts) BMI 35.6 (1.5) kg/m ²	n = 18 BMI 24.0 (0.6) kg/ m ²	80 mg PO	CL/F	63.4 (21) L/h	73.1 (16) L/h	NS	137
Propranolol ¹⁹⁹	n = 9 BMI 34.6 (5.6) kg/m ² TBW 99 kg	n = 9 BMI 21.4 (2.6) kg/ m ² TBW 60 kg	0.108 mg/kg IBW	CL	46.2 (10.5) L/h	41.6 (6.8) L/h	NS	138
Propranolol ¹⁹⁹	n = 12 TBW 110.3 (20.4) kg	n = 12 TBW 66.7 (6.8) kg	8 mg IV	CL	57.5 (18) L/h	75.9 (15) L/h	p < 0.01	140
Propranolol ¹⁹⁹	n = 6 TBW 136.5 (36) kg	n = 6 TBW 66.8 (11) kg	10 mg IV	CL	780 (20) mL/min	780 (10) mL/min	NS	139

Table 11 (continued)

Substrate (reference) ^a	Obese pts ^b	Non-obese pts ^b	Dose	Clearance			Signifi- cance	Weight normalized clearance (obese vs non-obese pts) ^{b,c}	Refer- ence
				Parameter	Obese pts ^b	Non-obese pts ^b			
Propranolol ¹⁹⁹	n = 6 TBW 136.5 (36) kg	n = 6 TBW 66.8 (11) kg	40 mg PO	CL	2.4 (0.2) L/min	2.8 (0.2) L/min	NS	0.02 vs 0.04 L/min/kg	139
Labetalol ²⁰⁰	n = 9 TBW 99 (23) kg BMI 34.6 (5.6) kg/m ²	n = 9 TBW 60 (11) kg BMI 21.4 (2.6) kg/ m ²	Mean 60.7–61.9 mg (p > 0.05)	CL	89.9 (11) L/h	81.5 (15) L/h	NS	0.91 vs 1.36 L/h/kg	138
Verapamil ²⁰¹⁻²⁰²	n = 12 (hypertensive pts) TBW 127 (8) kg	n = 11 (hypertensive pts) TBW 74 (4) kg	0.15 mg/kg; maximum 25 mg IV	CL	1.34 (0.2) L/min	1.25 (0.1) L/min	NS	0.01 vs 0.02 L/h/kg	142
Lidocaine ²⁰³	n = 14 (men) TBW 124 (8) kg	n = 19 (men) TBW 69 (1) kg	25 mg IV	CL	1427 (120) mL/min	1346 (86) mL/ min	NS	11.51 vs 19.51 mL/ min/kg	143
Lidocaine ²⁰³	n = 11 (women) TBW 96 (6) kg	n = 12 (women) TBW 59 (2) kg	25 mg IV	CL	1089 (83) mL/min	1162 (84) mL/ min	NS	11.34 vs 19.69 mL/ min/kg	143
Fentanyl ^{145,204}	n = 10 TBW 117.3 (33) kg	n = 16 TBW 68.5 (9.5) kg	Bolus and infusion rate based on kg TBW	CL	986 (155) mL/min	718 (163) mL/ min	p < 0.001	8.76 vs 10.48 mL/ min/kg (p < 0.025)	149

^a The references mentioned with the substrate (first column) refer to literature in which the drug is mentioned as a high-extraction-ratio drug.

^b Unless otherwise specified, mean values (standard deviation or range).

^c See section Approach for calculation of weight-normalized clearance values.

^d Values are expressed as range.

BMI = body mass index; CL = clearance; CL/F = oral clearance; IBW = ideal body weight; IV = intravenously; NA = not available; NS = not significant; PO = orally; TBW = total body weight.

non-obese patients¹³⁷⁻¹³⁹, and one study found significantly lower propranolol clearance values in obese versus non-obese patients¹⁴⁰. Propranolol clearance is strongly determined by liver blood flow as it approaches liver blood flow values¹⁴¹. On the other hand, propranolol tends to decrease liver blood flow by ~20-30% by blocking the beta-adrenoreceptor, explaining the relative lower clearance value seen for propranolol compared with other drugs in Table 11¹⁴¹.

Labetalol clearance in obese patients showed a trend towards being increased¹³⁸. For verapamil and lidocaine, no difference in clearance between obese and non-obese was found¹⁴²⁻¹⁴³. As lidocaine clearance is determined mainly by liver blood flow¹⁴⁴, the authors concluded that extreme total body weights did not change liver blood flow.

Sufentanil and fentanyl are predominantly metabolized by CYP3A4¹⁴⁵, but their total clearance is mainly determined by liver blood flow¹⁴⁶⁻¹⁴⁷. Sufentanil showed higher clearance values in obese versus non-obese patients; however, this difference was not statistically significant¹⁴⁸. The difference in body weight between the two groups studied was small (90 versus 74 kg). The pharmacokinetics of fentanyl were studied in a population with a wide range of total body weights, showing a non-linear positive correlation between total body weight and fentanyl clearance¹⁴⁹. Reported paclitaxel clearance values in obese and non-obese patients are extremely high (291 – 431 L/h), indicating liver blood flow-dependent clearance¹⁵⁰. Clearance values for paclitaxel in obese patients were higher than values of non-obese patients; however, this was not statistically significant⁵⁹.

In conclusion, only a few high-extraction-ratio drug studies in Table 11 showed altered clearance values in obese versus non-obese adults. Body weight-normalized clearance values show a large decrease in clearance per kilogram. For instance, the clearance per kilogram values of propranolol and lidocaine are almost halved. A straightforward conclusion from these studies is complicated because of the heterogeneity of the drugs. Liver blood flow is about 2–2.5 L/min, while clearance values of some drugs listed in table XI are less than 1 L/min, obscuring the justification of their role as a model drug for liver blood flow. When considering drugs with clearance values of more than 1.5 L/min (propofol, sufentanil and paclitaxel), all studies show higher clearances in obese patients. Propranolol was excluded from this comparison, as this drug shows high variability in drug clearance values among studies (Table 11). The observation of increased clearance is not statistically significant for sufentanil and paclitaxel, probably because of the small difference in total body weight in these studies. Unfortunately, the data from these studies did not allow comparison of weight-normalized clearance values.

Summary of liver blood flow

According to the results of propofol, sufentanil and paclitaxel studies, liver blood flow is likely to be increased in obese patients. However, only a few (very) high-extraction-ratio drugs have been studied and the difference in body weights between patients groups

was limited for sufentanil and paclitaxel. To our knowledge, no studies have investigated the pharmacokinetics of high-extraction-ratio drugs in children.

RENAL ELIMINATION

The kidneys are the primary organs involved in the elimination of drugs. The processes involved in drug elimination through the kidneys include glomerular filtration, tubular secretion and tubular reabsorption. The exact effect of obesity on these functions is not clear²⁵. Renal function seems to be affected, as obese patients showed a 62% increase in the mean estimated glomerular filtration rate (eGFR)¹⁵¹. This finding was observed, irrespective of the presence of hypertension by an increase of renal blood flow¹⁵². Obesity is related to a state of glomerular hyperfiltration, which resembles that seen in early-stage diabetic nephropathy and sickle cell disease^{20-21, 153}. It has been argued that overweight may ultimately lead to end-stage renal disease, because focal glomerular sclerosis and/or diabetic nephropathy have been observed in a small study in 17 morbidly obese patients who presented with proteinuria¹⁵⁴. In obese children, it was found that the glomerular filtration rate increases with BMI¹⁵⁵. In contrast to obese adults, obese children showed a higher degree of albuminuria, a marker for glomerular dysfunction¹⁵⁶⁻¹⁵⁷. Therefore, it was concluded that albuminuria indicates early renal glomerular dysfunction as a consequence of childhood obesity¹⁵⁶. However, obese children compared with non-obese children did not differ in their glomerular filtration rates, as no overt changes in eGFR were detected¹⁵⁷.

The influence of obesity on renal tubular secretion and renal tubular reabsorption is not well known, and no objective clinical measure of these drug clearance pathways presently exists¹⁵¹. Tubular dysfunction can be defined as the presence of at least two of the following criteria: nondiabetic glycosuria, urine phosphate wasting, hyperaminoaciduria, beta-2-microglobulinuria, and increased fractional excretion of uric acid¹⁵⁸⁻¹⁵⁹. For obese children, an increased degree of beta-2-microglobulinuria, suggesting increased tubular dysfunction, has been described¹⁵⁶.

In this section, we will provide an overview of clinical studies investigating drugs that are primarily eliminated renally and were studied in both non-obese and obese adults and children.

Glomerular filtration

In Table 12, an overview of studies comparing clearance of drugs that are mainly excreted by glomerular filtration in obese and non-obese individuals is presented. These drugs include vancomycin, daptomycin, carboplatin, low-molecular-weight heparins and cimetidine.

Table 12 Glomerular filtration-mediated clearance in both obese and non-obese patients (pts)

Substrate (reference) ^a	Clearance								
	Obese pts ^b	Non-obese pts ^b	Dose	Parameter	Obese pts ^b	Non-obese pts ^b	Signifi- cance	Weight normalized clearance (obese vs non-obese pts) ^{b,c}	Refer- ence
Vancomycin ²⁰⁵	n = 24 TBW 165 (46) kg	n = 24 TBW 68 (6) kg	TDM guided	CL	197 (77) mL/ min	77 (22) mL/ min	p < 0.001	1.19 vs 1.13 mL/ min/kg	160
Daptomycin ²⁰⁶	n = 7 TBW 114 (16) kg	n = 7 TBW 59 (6) kg	4 mg/kg based on TBW	CL	0.82 (0.21) L/h	0.73 (0.14) L/h	p = 0.34	0.43 vs 0.74 L/min/kg	161
Daptomycin ²⁰⁶	n = 7 (obese pts) TBW 86 (9) kg	n = 12 TBW 64 (7) kg	4 mg/kg based on TBW	CL	0.86 (CV8%) L/h	0.72 (CV 6%) L/h	p = 0.008	10.07 vs 11.89 mL/h/ kg	162
	n = 6 (morbidly obese pts) TBW 126 (17) kg				1.01 (CV 29%) L/h	0.70 (CV 34%) L/h	p = 0.003	7.82 vs 10.19 mL/h/ kg	
Carboplatin ¹⁶³	n = 15 BMI >30 kg/m ²	n = 218 BMI <30 kg/m ²	Protocol based	CL	Related to adjusted IBW		No dose adjustment needed in obese pts	NA	165
Carboplatin ¹⁶³	n = 14 BMI >30 kg/m ²	n = 64 BMI <30 kg/m ²	Based on renal function	CL	6.48 L/h	5.88 L/h	p = 0.37	NA	(59)
Carboplatin ¹⁶³	n = 43 BMI >30 kg/m ²	n = 285 BMI >18.5 kg/m ² and <30 kg/m ²	Based on renal function	CL	Increased with TBW		No dose adjustment needed in obese pts	NA	164
Enoxaparin ²⁰⁷	n = 118 TBW 43–120 ^d kg		1.0–1.5 mg/kg bid	CL	CL = 0.3 • CL _{cr} /70 + 0.42 • LBW/55 (kg)		p < 0.001	NA	208
Dalteparin ²⁰⁷	n = 10 TBW 106 (22) kg	n = 10 TBW 70 (9) kg	Protocol based	CL	1.30 L/h	1.11 L/h	NS	0.74 vs 0.95 L/min/kg	209

Table 12 (continued)

Substrate (reference) ^a	Obese pts ^b	Non-obese pts ^b	Dose	Clearance				Reference	
				Parameter	Obese pts ^b	Non-obese pts ^b	Signifi- cance		Weight normalized clearance (obese vs non-obese pts) ^{b,c}
Tinzaparin ²⁰⁷	n = 425 TBW 37–151 ^d kg		175 IU/kg od	CL	22% decrease in CL in L/h/ kg in obese pts (BMI > 30 kg/m ²)			NA	210
Cimetidine ²¹¹	n = 13 TBW 113 (9) kg	n = 16 TBW 64 (2) kg	200–300 mg IV	CL	616 (34) mL/ min	579 (39) mL/min	NS	5.45 vs 9.05 mL/ min/kg	167

a The references mentioned with the substrate (first column) refer to literature in which the appropriateness of the particular drug as a GFR probe was confirmed.
b Unless otherwise specified, mean values (standard deviation).

c See section Approach for calculation of weight-normalized clearance values.

d Values are expressed as range.

bid = twice daily; BMI = body mass index; CL = clearance; CL_{Cr} = creatinine clearance; CV% = coefficient of variation; GFR = glomerular filtration rate; IBW = ideal body weight; IV = intravenously; LBW = lean body weight; NA = not available; NS = not significant; od = once daily; TBW = total body weight; TDM = therapeutic drug monitoring.

Vancomycin clearance in morbidly obese patients is reported to increase with total body weight, compared with non-obese patients¹⁶⁰. No significant increase of daptomycin clearance was described in obese patients with a mean total body weight of 114 kg¹⁶¹. However, in patients with a higher mean total body weight (126 kg), significantly higher daptomycin clearance was reported¹⁶². Carboplatin is mainly eliminated by glomerular filtration and partly by tubular secretion¹⁶³. Both a linear increase of carboplatin clearance with total body weight¹⁶⁴ and ideal body weight¹⁶⁵ have been described. A comparison of carboplatin clearance values between obese and non-obese patients showed no significant difference⁵⁹. The low-molecular-weight heparins enoxaparin, tinzaparin and dalteparin show higher total drug clearance in obese patients compared with non-obese patients (166-168). Studies on the influence of obesity on drug clearance mediated by glomerular filtration in obese children are very limited. In obese children, lower anti-Xa levels after the same dose of enoxaparin were reported, suggesting higher enoxaparin clearance in obese children¹⁶⁶. In contrast to these studies, total clearance of cimetidine was not altered in obese patients compared with non-obese patients¹⁶⁷.

In conclusion, the majority of these studies show higher clearance values with increasing body weights, indicating increased glomerular filtration in obese patients. Weight-normalized clearance values did not show a consistent trend for the influence of overweight on glomerular filtration, as normalized clearance values were either equal or lower in obese as compared with normal-weight patients.

Tubular secretion

Drugs that are (partly) eliminated by tubular secretion and have been investigated in obese patients are summarized in Table 13 and include procainamide, ciprofloxacin, cisplatin, topotecan and digoxin.

Approximately 50% of administered procainamide is eliminated as unchanged drug by glomerular filtration and active tubular secretion¹⁶⁸. Renal procainamide clearance was shown to be higher in obese patients because of elevated tubular secretion, as no significant difference in 24-hour creatinine clearance was observed between obese and non-obese patients¹²⁷. Significantly higher clearance values were also reported for cisplatin and ciprofloxacin, which are eliminated by tubular secretion^{59, 169-171}. For both topotecan and digoxin, there was a trend towards higher drug clearance in obese patients, which is assumed to result from increased tubular secretion^{59, 172}. For tubular secretion, normalized clearance values per kilogram were equal or slightly lower in obese as compared with non-obese patients.

In conclusion, these studies indicate higher tubular secretion in obese as compared with non-obese individuals. To date, no information is available on the impact of obesity on the tubular secretion of drugs in children.

Table 13 Tubular secretion-mediated clearance in both obese and non-obese patients (pts)

Substrate (reference) ^a	Clearance					Reference			
	Obese pts ^b	Non-obese pts ^b	Dose	Parameter	Obese pts ^b		Non-obese pts ^b	Significance	Weight normalized clearance (obese vs non-obese pts) ^{b,c}
Procainamide ¹⁶⁸	n = 7 TBW 100 (17) kg	n = 7 TBW 68 (12) kg	300 mg IV	CL	4.19 (1.13) mL/min ^d	2.68 (0.85) mL/min ^d	0.05 > p > 0.02	0.04 vs 0.04 mL/ min/kg	127
Ciprofloxacin ¹⁶⁹	n = 17 TBW 111 (20) kg	n = 11 TBW 72 (10) kg	400 mg IV	CL	638 mL/min	495 mL/min	p < 0.05	5.74 vs 6.88 mL/ min/kg	170
Cisplatin ¹⁷¹	n = 23 BMI <30 kg/m ²	n = 165 BMI <30 kg/m ²	50–100 mg/m ²	CL	60 L/h	53.3 L/h	p = 0.007	NA	59
Topotecan ²¹²	n = 21 BMI >30 kg/m ²	n = 108 BMI <30 kg/m ²	Protocol based	CL	21.7 L/h	19.6 L/h	p = 0.50	NA	59
Digoxin ²¹³	n = 13 TBW 100 kg	n = 16 TBW 65 kg	0.75 mg IV	CL	328 mL/min	278 mL/min	T-value 1.59 (NS)	3.28 vs 4.28 mL/ min/kg	172

a The references mentioned with the substrate (first column) refer to literature in which the appropriateness of the particular drug as a tubular secretion probe was confirmed.

b Unless otherwise specified, mean values (standard deviation).

c See section Approach for calculation of weight-normalized clearance values.

d Corrected for CL_{cr}.

BMI = body mass index; CL = clearance; CL_{cr} = creatinine clearance; IV = intravenously; NA = not available; NS = not significant; TBW = total body weight.

Table 14 Tubular reabsorption-mediated clearance in both obese and non-obese patients (pts)

Substrate (reference) ^a	Obese pts ^b	Non-obese pts ^b	Dose	Clearance					Reference
				Parameter	Obese pts ^b	Non-obese pts ^b	Significance	Weight normalized clearance (obese vs non-obese pts) ^{b,c}	
Lithium ²¹⁴	n = 10 TBW 110 (29) kg	n = 8 TBW 63 (7) kg	31.4 mEq	CL	33.9 (7.0) mL/min	23.0 (6.2) mL/min	p = 0.005	0.31 vs 0.37 mL/min/kg	173

a The references mentioned with the substrate (first column) refer to literature in which the appropriateness of the particular drug as a tubular reabsorption probe was confirmed.

b Unless otherwise specified, mean values (standard deviation).

c See section Approach for calculation of weight-normalized clearance values.

CL = clearance; mEq = milliequivalents; TBW = total body weight.

Tubular reabsorption

Studies on the influence of obesity on the tubular reabsorption of drugs are scarce (Table 14). Tubular reuptake of lithium in obese patients was reported to be lower, as lithium clearance was significantly increased in obese patients and glomerular filtration did not differ between these obese and non-obese patients¹⁷³. In contrast, proximal tubular reabsorption of sodium in obese patients is reported to be increased because of glomerular hyperfiltration¹⁷⁴.

Summary of renal elimination

The reviewed studies show that clearance of renally eliminated drug is higher in obese patients because of increased glomerular filtration and tubular secretion. The influence of obesity on the tubular reabsorption is unknown, as there is a lack of evidence on this topic.

DISCUSSION AND CONCLUSIONS

In this review, we have summarized the effects of obesity on drug metabolism and elimination. Studies that investigated pharmacokinetics of drugs in both obese and non-obese individuals were classified according to the drug's most important metabolic or elimination pathway. This allowed us to structurally review the influence of obesity on each individual metabolic or elimination pathway. Metabolic processes were subdivided into phase I metabolism, phase II metabolism and liver blood flow-dependent metabolism. Renal elimination was subdivided into glomerular filtration and tubular processes.

The reviewed studies show that the impact of obesity on drug metabolism and elimination differs greatly, depending on the metabolic or elimination pathway primarily involved in the handling of the investigated drug. In particular, CYP3A4-mediated drug elimination was found to be consistently lower, while UGT-, CYP2E1-, arylamine *N*-acetyltransferase type 2- and xanthine oxidase- mediated drug metabolism was consistently higher among obese as compared with non-obese subjects. Clearance mediated by phase I metabolizing enzymes CYP1A2, CYP2C9, CYP2C19 and CYP2D6 show trends towards higher clearance values in obese individuals.

Studies on drug clearance mediated by liver blood flow are somewhat inconclusive, although, on the basis of a few highly extracted drugs, an increase in liver blood flow can be noted in obese patients.

Regarding drug elimination, the reviewed studies show an increase of glomerular filtration and tubular secretion in obese patients. The influence of obesity on tubular reabsorption is unknown.

Many of the observed trends were also reflected in weight-normalized clearance values, which were halved (e.g. CYP3A4), almost equal (e.g. CYP2E1) or slightly decreased in obese as compared with non-obese individuals (e.g. CYP2C9 and tubular secretion). For other drug clearance pathways, trends in body weight-normalized clearance were not as pronounced (e.g. the glomerular filtration rate and CYP1A2). It should be emphasized that these body weight-normalized clearance values may provide information on quantitative differences in clearance values but do not explain the relationship between total body weight and drug clearance values.

The large number of studies included in this review shows that there is a substantial amount of information available on the impact of obesity on drug metabolism and elimination. However, in many of these studies, the difference in body weight between obese and non-obese subjects is rather small. More specifically, the obese subjects included in the reviewed studies are not as obese as the patients currently seeking medical care. From this perspective, information on drug metabolism and elimination in morbidly obese patients (BMI >40 kg/m²) and super-obese patients (BMI >50 kg/m²) is largely lacking and requires future research.

Regarding obesity in children, only five studies investigated pharmacokinetics of a drug in obese versus non-obese children, of which four were recently published^{78,92,117,132}. Regarding renal elimination, no pharmacokinetic studies of obese versus non-obese children were found. Extrapolation of results from studies in obese adults to obese children is widely applied because often no clinical studies in obese children are available^{24,175}. For the UGT mediated metabolism of paracetamol this may be justified, as paracetamol clearance in both adolescents⁷⁸ and adults⁷⁹ was increased. This strong similarity in results was not seen for other drugs that were studied in both adults and children such as caffeine⁹². Moreover, the expression and activity of enzymatic pathways in children

may be different compared with adults and are dependent on maturational status (age). In addition, obesity may influence the maturation process(es) itself, and the starting point of weight gain may also influence the maturation process(es), representing additional factors of variability in drug metabolism and elimination among obese adults and children. Taking this into consideration, extrapolation from adult observations may give false predictions of clearance values in children (and vice versa) and should be performed with care.

While it is impossible to study and assess the pharmacokinetics of every drug in obese subjects, future clinical trials should aim to quantify the impact of obesity on specific drug elimination pathways and on the underlying associated mechanisms (e.g. steatosis and inflammation). In this approach, study outcomes can be extrapolated to other drugs eliminated by the same pathway. This extrapolation can be achieved by using model drugs and within the context of a multidisciplinary research team including physicians, pharmacists, pharmacologists and pharmacometricians. Primarily, future research in this area should focus on individual metabolic and elimination pathways in adults and children that show increasing or decreasing trends in activity among obese versus non-obese individuals. As concluded from this review, these pathways include CYP3A4, CYP2E1, xanthine oxidase, UGT, *N*-acetyltransferase, glomerular filtration and tubular processes. Mainly, CYP3A4 deserves immediate research attention. Finally, particularly obese children and adolescents, and morbidly obese (BMI >40 kg/m²) and super-obese patients (BMI >50 kg/m²) should be included in these studies.

In conclusion, this systematic review of pharmacokinetic studies in obese and non-obese patients shows that the impact of obesity on drug metabolism and elimination greatly differs per drug metabolic or elimination pathway. However, the clinical trials reviewed here often only included overweight to moderately obese patients. As the prevalence of obesity and total body weights of both children and adults are still increasing and this trend will persist, future studies assessing the impact of morbid obesity on specific drug elimination pathways in both children and adults are warranted.

ACKNOWLEDGEMENTS

John van den Anker and Catherijne Knibbe contributed equally to this work.

The authors declare no conflicts of interest that are directly relevant to the content of this review. The authors thank Sabine Ahlers and Saskia de Mik-van Ham for critically reading the manuscript.

REFERENCES

1. Centers for Disease Control and Prevention. 2009. (Accessed 3 may 2011, 2011, at <http://www.cdc.gov/obesity/data/trends.html>.)
2. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. *Jama*;303:235-41.
3. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. *Jama* 2006;295:1549-55.
4. IASO. International Association for the Study of Obesity. In.
5. Ogden CL, Carroll MD, Curtin LR, Lamb MM, Flegal KM. Prevalence of high body mass index in US children and adolescents, 2007-2008. *Jama* 2010;303:242-9.
6. Jia WP, Wang C, Jiang S, Pan JM. Characteristics of obesity and its related disorders in China. *Biomed Environ Sci* 2010;23:4-11.
7. Kelly T, Yang W, Chen CS, Reynolds K, He J. Global burden of obesity in 2005 and projections to 2030. *Int J Obes (Lond)* 2008;32:1431-7.
8. Cheymol G. Clinical pharmacokinetics of drugs in obesity. An update. *Clin Pharmacokinet* 1993; 25:103-14.
9. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. *Clin Pharmacokinet* 2000;39:215-31.
10. Alexander JK, Dennis EW, Smith WG, Amad KH, Duncan WC, Austin RC. Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity. *Cardiovasc Res Cent Bull* 1962;1:39-44.
11. Zavorsky GS. Cardiopulmonary aspects of obesity in women. *Obstet Gynecol Clin North Am* 2009; 36:267-84, viii.
12. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. *J Clin Invest* 2005;115:1111-9.
13. Guzzaloni G, Grugni G, Minocci A, Moro D, Morabito F. Liver steatosis in juvenile obesity: correlations with lipid profile, hepatic biochemical parameters and glycemic and insulinemic responses to an oral glucose tolerance test. *Int J Obes Relat Metab Disord* 2000;24:772-6.
14. Wree A, Kahraman A, Gerken G, Canbay A. Obesity affects the liver - the link between adipocytes and hepatocytes. *Digestion* 2011;83:124-33.
15. Fisher CD, Lickteig AJ, Augustine LM, et al. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. *Drug Metab Dispos* 2009;37: 2087-94.
16. Donato MT, Lahoz A, Jimenez N, et al. Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts. *Drug Metab Dispos* 2006;34:1556-62.
17. Donato MT, Jimenez N, Serralta A, Mir J, Castell JV, Gomez-Lechon MJ. Effects of steatosis on drug-metabolizing capability of primary human hepatocytes. *Toxicol In Vitro* 2007;21:271-6.
18. Emery MG, Fisher JM, Chien JY, et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. *Hepatology* 2003;38:428-35.
19. Casati A, Putzu M. Anesthesia in the obese patient: pharmacokinetic considerations. *J Clin Anesth* 2005;17:134-45.
20. Marik P VJ. The obese patient in the ICU. *Chest* 1998;113:492-8.
21. Darbari DS, Neely M, van den Anker J, Rana S. Increased clearance of morphine in sickle cell disease: implications for pain management. *J Pain* 2011;12:531-8.
22. Jain R, Chung SM, Jain L, et al. Implications of obesity for drug therapy: limitations and challenges. *Clin Pharmacol Ther* 2011;90:77-89.

23. Abernethy DR, Greenblatt DJ. Drug disposition in obese humans. An update. *Clin Pharmacokinet* 1986;11:199-213.
24. Mulla H, Johnson TN. Dosing dilemmas in obese children. *Arch Dis Child Educ Pract Ed* 2010;95: 112-7.
25. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. *Clin Pharmacokinet* 2010;49:71-87.
26. Ingrande J, Lemmens HJ. Dose adjustment of anaesthetics in the morbidly obese. *Br J Anaesth* 2010;105:16-23.
27. Morrish GA, Pai MP, Green B. The effects of obesity on drug pharmacokinetics in humans. *Expert Opin Drug Metab Toxicol* 2011.
28. Abernethy DR, Greenblatt DJ. Pharmacokinetics of drugs in obesity. *Clin Pharmacokinet* 1982;7: 108-24.
29. Kotlyar M, Carson SW. Effects of obesity on the cytochrome P450 enzyme system. *Int J Clin Pharmacol Ther* 1999;37:8-19.
30. Edelman AB, Cherala G, Stanczyk FZ. Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review. *Contraception* 2010;82:314-23.
31. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? *Br J Clin Pharmacol* 2004;58:119-33.
32. Drug Interactions: Cytochrome P450 Drug Interaction Table *version 5.0*. Indiana University School of Medicine, 2007. (Accessed May 4 2011, 2011, at <http://medicine.iupui.edu/clinpharm/ddis/table.asp>.)
33. Williams RT. Detoxication Mechanisms: The Metabolism and Detoxication of Drugs, Toxic Substances, and Other Organic Compounds. 2nd ed. London: Chapman and Hall; 1959.
34. Moretto M, Kupski C, Mottin CC, et al. Hepatic steatosis in patients undergoing bariatric surgery and its relationship to body mass index and co-morbidities. *Obes Surg* 2003;13:622-4.
35. Silverman JF, O'Brien KF, Long S, et al. Liver pathology in morbidly obese patients with and without diabetes. *Am J Gastroenterol* 1990;85:1349-55.
36. Harnois F, Msika S, Sabate JM, et al. Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery. *Obes Surg* 2006;16: 183-8.
37. Thorn M, Finnstrom N, Lundgren S, Rane A, Loof L. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. *Br J Clin Pharmacol* 2005;60:54-60.
38. Lindell M, Karlsson MO, Lennernas H, Pahlman L, Lang MA. Variable expression of CYP and Pgp genes in the human small intestine. *Eur J Clin Invest* 2003;33:493-9.
39. Guengerich FP. Cytochrome p450 and chemical toxicology. *Chem Res Toxicol* 2008;21:70-83.
40. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. *Science* 1999;286:487-91.
41. Hunt CM, Westerkam WR, Stave GM, Wilson JA. Hepatic cytochrome P-4503A (CYP3A) activity in the elderly. *Mech Ageing Dev* 1992;64:189-99.
42. Hunt CM, Watkins PB, Saenger P, et al. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. *Clin Pharmacol Ther* 1992;51:18-23.
43. Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. *Clin Pharmacokinet* 2007;46:681-96.
44. Watkins PB. The role of cytochromes P-450 in cyclosporine metabolism. *J Am Acad Dermatol* 1990;23:1301-9; discussion 9-11.

45. Kerr BM, Thummel KE, Wurden CJ, et al. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. *Biochem Pharmacol* 1994;47:1969-79.
46. Streetman DS, Bertino JS, Jr., Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. *Pharmacogenetics* 2000;10:187-216.
47. Abernethy DR, Greenblatt DJ, Divoll M, Smith RB, Shader RI. The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. *Clin Pharmacokinet* 1984;9:177-83.
48. Greenblatt DJ, Abernethy DR, Locniskar A, Harmatz JS, Limjuco RA, Shader RI. Effect of age, gender, and obesity on midazolam kinetics. *Anesthesiology* 1984;61:27-35.
49. Yee GC, Lennon TP, Gmur DJ, Cheney CL, Oeser D, Deeg HJ. Effect of obesity on cyclosporine disposition. *Transplantation* 1988;45:649-51.
50. Flechner SM, Kolbeinson ME, Tam J, Lum B. The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients. *Transplantation* 1989;47:806-10.
51. Caraco Y, Zylber-Katz E, Berry EM, Levy M. Carbamazepine pharmacokinetics in obese and lean subjects. *Ann Pharmacother* 1995;29:843-7.
52. Caraco Y, Zylber-Katz E, Berry EM, Levy M. Significant weight reduction in obese subjects enhances carbamazepine elimination. *Clin Pharmacol Ther* 1992;51:501-6.
53. Kharasch ED, Russell M, Mautz D, et al. The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. *Anesthesiology* 1997;87:36-50.
54. Bentley JB, Finley JH, Humphrey LR, Gandolfi AJ, Brown BR. Obesity and Alfentanil Pharmacokinetics. *Anesth Analg* 1983;62:251.
55. Reddy VB, Doss GA, Karanam BV, et al. In vitro and in vivo metabolism of a novel cannabinoid-1 receptor inverse agonist, taranabant, in rats and monkeys. *Xenobiotica* 2010;40:650-62.
56. Li XS, Nielsen J, Cirincione B, et al. Development of a population pharmacokinetic model for taranabant, a cannabinoid-1 receptor inverse agonist. *AAPS J* 2010;12:537-47.
57. Rotzinger S, Fang J, Baker GB. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. *Drug Metab Dispos* 1998;26:572-5.
58. Mihara K, Otani K, Suzuki A, et al. Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. *Psychopharmacology (Berl)* 1997;133:95-8.
59. Sparreboom A, Wolff AC, Mathijssen RH, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. *J Clin Oncol* 2007;25:4707-13.
60. Marterre WF, Hariharan S, First MR, Alexander JW. Gastric bypass in morbidly obese kidney transplant recipients. *Clin Transplant* 1996;10:414-9.
61. Boni J, Leister C, Burns J, Cincotta M, Hug B, Moore L. Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications. *J Clin Pharmacol* 2007;47:1430-9.
62. Kamdem LK, Streit F, Zanger UM, et al. Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. *Clin Chem* 2005;51:1374-81.
63. Picard N, Cresteil T, Premaud A, Marquet P. Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. *Ther Drug Monit* 2004;26:600-8.
64. Rogers CC, Alloway RR, Alexander JW, Cardi M, Trofe J, Vinks AA. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. *Clin Transplant* 2008;22:281-91.
65. Skottheim IB, Jakobsen GS, Stormark K, et al. Significant increase in systemic exposure of atorvastatin after biliopancreatic diversion with duodenal switch. *Clin Pharmacol Ther* 2010;87:699-705.

66. Skottheim IB, Stormark K, Christensen H, et al. Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients. *Clin Pharmacol Ther* 2009; 86:311-8.
67. Lucas D, Ferrara R, Gonzalez E, et al. Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans. *Pharmacogenetics* 1999;9:377-88.
68. O'Shea D, Davis SN, Kim RB, Wilkinson GR. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. *Clin Pharmacol Ther* 1994;56: 359-67.
69. Lucas D, Farez C, Bardou LG, Vaisse J, Attali JR, Valensi P. Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. *Fundam Clin Pharmacol* 1998; 12:553-8.
70. Kharasch ED, Thummel KE, Mautz D, Bosse S. Clinical enflurane metabolism by cytochrome P450 2E1. *Clin Pharmacol Ther* 1994;55:434-40.
71. Kharasch ED. Biotransformation of sevoflurane. *Anesth Analg* 1995;81:S27-38.
72. Reichle FM, Conzen PF. Halogenated inhalational anaesthetics. *Best Pract Res Clin Anaesthesiol* 2003;17:29-46.
73. Miller MS, Gandolfi AJ, Vaughan RW, Bentley JB. Disposition of enflurane in obese patients. *J Pharmacol Exp Ther* 1980;215:292-6.
74. Bentley JB, Vaughan RW, Miller MS, Calkins JM, Gandolfi AJ. Serum inorganic fluoride levels in obese patients during and after enflurane anesthesia. *Anesth Analg* 1979;58:409-12.
75. Higuchi H, Satoh T, Arimura S, Kanno M, Endoh R. Serum inorganic fluoride levels in mildly obese patients during and after sevoflurane anesthesia. *Anesth Analg* 1993;77:1018-21.
76. Frink EJ, Jr., Malan TP, Jr., Brown EA, Morgan S, Brown BR, Jr. Plasma inorganic fluoride levels with sevoflurane anesthesia in morbidly obese and nonobese patients. *Anesth Analg* 1993;76:1333-7.
77. Bentley JB, Vaughan RW, Gandolfi AJ, Cork RC. Halothane biotransformation in obese and non-obese patients. *Anesthesiology* 1982;57:94-7.
78. Barshop NJ, Capparelli EV, Sirlin CB, Schwimmer JB, Lavine JE. Acetaminophen pharmacokinetics in children with nonalcoholic fatty liver disease. *J Pediatr Gastroenterol Nutr* 2011;52:198-202.
79. Abernethy DR, Divoll M, Greenblatt DJ, Ameer B. Obesity, sex, and acetaminophen disposition. *Clin Pharmacol Ther* 1982;31:783-90.
80. Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. *J Toxicol Clin Toxicol* 2002;40:3-20.
81. May DG. Genetic differences in drug disposition. *J Clin Pharmacol* 1994;34:881-97.
82. van den Anker JN. Developmental pharmacology. *Dev Disabil Res Rev* 2010;16:233-8.
83. Cheymol G, Weissenburger J, Poirier JM, Gellee C. The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. *Br J Clin Pharmacol* 1995;39:684-7.
84. Cheymol G, Woestenborghs R, Snoeck E, et al. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. *Eur J Clin Pharmacol* 1997;51:493-8.
85. Lefebvre J, Poirier L, Poirier P, Turgeon J, Lacourciere Y. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension. *Br J Clin Pharmacol* 2007; 63:575-82.
86. Schrenk D, Brockmeier D, Morike K, Bock KW, Eichelbaum M. A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers. *Eur J Clin Pharmacol* 1998;53:361-7.
87. Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GT. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. *Pharmacogenetics* 1996;6:121-49.

88. Rasmussen BB, Brosen K. Theophylline has no advantages over caffeine as a putative model drug for assessing CYP1A2 activity in humans. *Br J Clin Pharmacol* 1997;43:253-8.
89. Caraco Y, Zylber-Katz E, Berry EM, Levy M. Caffeine pharmacokinetics in obesity and following significant weight reduction. *Int J Obes Relat Metab Disord* 1995;19:234-9.
90. Kamimori GH, Somani SM, Knowlton RG, Perkins RM. The effects of obesity and exercise on the pharmacokinetics of caffeine in lean and obese volunteers. *Eur J Clin Pharmacol* 1987;31:595-600.
91. Abernethy DR, Todd EL, Schwartz JB. Caffeine disposition in obesity. *Br J Clin Pharmacol* 1985;20:61-6.
92. Chine M, Schwarzenberg SJ, Johnson LA. Altered xanthine oxidase and N-acetyl transferase activity in obese children. *Br J Clin Pharmacol* 2011.
93. Zahorska-Markiewicz B, Waluga M, Zielinski M, Klin M. Pharmacokinetics of theophylline in obesity. *Int J Clin Pharmacol Ther* 1996;34:393-5.
94. Jusko WJ, Gardner MJ, Mangione A, Schentag JJ, Koup JR, Vance JW. Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol. *J Pharm Sci* 1979;68:1358-66.
95. Blouin RA, Elgert JF, Bauer LA. Theophylline clearance: effect of marked obesity. *Clin Pharmacol Ther* 1980;28:619-23.
96. Gonzalez FJ, Idle JR. Pharmacogenetic phenotyping and genotyping. Present status and future potential. *Clin Pharmacokinet* 1994;26:59-70.
97. He SM, Zhou ZW, Li XT, Zhou SF. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development. *Curr Med Chem* 2011;18:667-713.
98. Abernethy DR, Greenblatt DJ. Phenytoin disposition in obesity. Determination of loading dose. *Arch Neurol* 1985;42:468-71.
99. Abernethy DR, Greenblatt DJ. Ibuprofen disposition in obese individuals. *Arthritis Rheum* 1985;28:1117-21.
100. Langtry HD, Balfour JA. Glimepiride. A review of its use in the management of type 2 diabetes mellitus. *Drugs* 1998;55:563-84.
101. Shukla UA, Chi EM, Lehr KH. Glimepiride pharmacokinetics in obese versus non-obese diabetic patients. *Ann Pharmacother* 2004;38:30-5.
102. Tan B, Zhang YF, Chen XY, Zhao XH, Li GX, Zhong DF. The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects. *Eur J Clin Pharmacol* 2010;66:145-51.
103. Jaber LA, Ducharme MP, Halapy H. The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus. *Ther Drug Monit* 1996;18:6-13.
104. Flockhart DA. Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19. *Clin Pharmacokinet* 1995;29 Suppl 1:45-52.
105. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, Villen T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. *Clin Pharmacol Ther* 1989;45:348-55.
106. Abernethy DR, Greenblatt DJ, Divoll M, Harmatz JS, Shader RI. Alterations in drug distribution and clearance due to obesity. *J Pharmacol Exp Ther* 1981;217:681-5.
107. Abernethy DR, Greenblatt DJ, Divoll M, Shader RI. Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). *J Pharm Sci* 1982;71:942-4.

108. Strolin Benedetti M, Whomsley R, Baltes E. Involvement of enzymes other than CYPs in the oxidative metabolism of xenobiotics. *Expert Opin Drug Metab Toxicol* 2006;2:895-921.
109. Balis FM. Pharmacokinetic drug interactions of commonly used anticancer drugs. *Clin Pharmacokinet* 1986;11:223-35.
110. Zuccaro P, Guandalini S, Pacifici R, et al. Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia. *Ther Drug Monit* 1991;13:37-41.
111. Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. *Clin Pharmacol Ther* 1996;59:613-23.
112. Caraco Y, Zylber-Katz E, Berry EM, Levy M. Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism. *Eur J Clin Pharmacol* 1995;47:525-30.
113. Le Jeunne C, Poirier JM, Cheymol G, Ertzbischoff O, Engel F, Hugues FC. Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers. *Eur J Clin Pharmacol* 1991;41:171-4.
114. Westhoff CL, Torgal AH, Mayeda ER, Pike MC, Stanczyk FZ. Pharmacokinetics of a combined oral contraceptive in obese and normal-weight women. *Contraception* 2010;81:474-80.
115. Rudek MA, Sparreboom A, Garrett-Mayer ES, et al. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. *Eur J Cancer* 2004;40:1170-8.
116. Fukuchi H, Nakashima M, Araki R, et al. Effect of obesity on serum amiodarone concentration in Japanese patients: population pharmacokinetic investigation by multiple trough screen analysis. *J Clin Pharm Ther* 2009;34:329-36.
117. Thompson PA, Rosner GL, Matthay KK, et al. Impact of body composition on pharmacokinetics of doxorubicin in children: a Glaser Pediatric Research Network study. *Cancer Chemother Pharmacol* 2009;64:243-51.
118. Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyltransferases and clinical drug-drug interactions. *Pharmacol Ther* 2005;106:97-132.
119. Tchernof A, Levesque E, Beaulieu M, et al. Expression of the androgen metabolizing enzyme UGT2B15 in adipose tissue and relative expression measurement using a competitive RT-PCR method. *Clin Endocrinol (Oxf)* 1999;50:637-42.
120. Court MH, Duan SX, Guillemette C, et al. Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. *Drug Metab Dispos* 2002;30:1257-65.
121. Mutlib AE, Goosen TC, Bauman JN, Williams JA, Kulkarni S, Kostrubsky S. Kinetics of acetaminophen glucuronidation by UDP-glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity. *Chem Res Toxicol* 2006;19:701-9.
122. Hayakawa H, Fukushima Y, Kato H, et al. Metabolism and disposition of novel des-fluoro quinolone garenoxacin in experimental animals and an interspecies scaling of pharmacokinetic parameters. *Drug Metab Dispos* 2003;31:1409-18.
123. Van Wart S, Phillips L, Ludwig EA, et al. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. *Antimicrob Agents Chemother* 2004;48:4766-77.
124. Abernethy DR, Greenblatt DJ, Divoll M, Shader RI. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. *J Lab Clin Med* 1983;101:873-80.
125. Chung JY, Cho JY, Yu KS, et al. Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. *Clin Pharmacol Ther* 2005;77:486-94.

126. Okumura K, Kita T, Chikazawa S, Komada F, Iwakawa S, Tanigawara Y. Genotyping of N-acetylation polymorphism and correlation with procainamide metabolism. *Clin Pharmacol Ther* 1997;61: 509-17.
127. Christoff PB, Conti DR, Naylor C, Jusko WJ. Procainamide disposition in obesity. *Drug Intell Clin Pharm* 1983;17:516-22.
128. Gibbs JP, Gooley T, Corneau B, et al. The impact of obesity and disease on busulfan oral clearance in adults. *Blood* 1999;93:4436-40.
129. Nguyen L, Leger F, Lennon S, Puozzo C. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. *Cancer Chemother Pharmacol* 2006;57:191-8.
130. Buggia I, Zecca M, Alessandrino EP, et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. *GITMO (Gruppo Italiano Trapianto di Midollo Osseo)*. *Anticancer Res* 1996;16:2083-8.
131. Czerwinski M, Gibbs JP, Slaterry JT. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. *Drug Metab Dispos* 1996;24:1015-9.
132. Browning B, Thormann K, Donaldson A, Halverson T, Shinkle M, Kletzel M. Busulfan Dosing in Children with BMIs $\geq 85\%$ Undergoing HSCT: A New Optimal Strategy. *Biol Blood Marrow Transplant* 2011.
133. Farrell GC, Teoh NC, McCuskey RS. Hepatic microcirculation in fatty liver disease. *Anat Rec (Hoboken)* 2008;291:684-92.
134. Al-Jahdari WS, Yamamoto K, Hiraoka H, Nakamura K, Goto F, Horiuchi R. Prediction of total propofol clearance based on enzyme activities in microsomes from human kidney and liver. *Eur J Clin Pharmacol* 2006;62:527-33.
135. van Kralingen S, Diepstraten J, Peeters MYM, et al. Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients. *Clin Pharmacokinet* 2011;accepted for publication.
136. Cortinez LI, Anderson BJ, Penna A, et al. Influence of obesity on propofol pharmacokinetics: derivation of a pharmacokinetic model. *Br J Anaesth* 2010;105:448-56.
137. Wojcicki J, Jaroszynska M, Drozdziak M, Pawlik A, Gawronska-Szklarz B, Sterna R. Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipidemic and hyperlipidaemic obese subjects. *Biopharm Drug Dispos* 2003;24:211-8.
138. Cheymol G, Poirier JM, Carrupt PA, et al. Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers. *Br J Clin Pharmacol* 1997;43:563-70.
139. Bowman SL, Hudson SA, Simpson G, Munro JF, Clements JA. A comparison of the pharmacokinetics of propranolol in obese and normal volunteers. *Br J Clin Pharmacol* 1986;21:529-32.
140. Cheymol G, Poirier JM, Barre J, Pradalier A, Dry J. Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. *J Clin Pharmacol* 1987;27:874-9.
141. Routledge PA, Shand DG. Clinical pharmacokinetics of propranolol. *Clin Pharmacokinet* 1979;4: 73-90.
142. Abernethy DR, Schwartz JB. Verapamil pharmacodynamics and disposition in obese hypertensive patients. *J Cardiovasc Pharmacol* 1988;11:209-15.
143. Abernethy DR, Greenblatt DJ. Lidocaine disposition in obesity. *Am J Cardiol* 1984;53:1183-6.
144. Pea F, Licari M, Baldassarre M, Furlanut M. MEGX disposition in critically-ill trauma patients: subsequent assessments during the first week following trauma. *Fundam Clin Pharmacol* 2002;16: 519-25.

145. Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M. Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. *Anesth Analg* 1996;82:167-72.
146. Gepts E, Shafer SL, Camu F, et al. Linearity of pharmacokinetics and model estimation of sufentanil. *Anesthesiology* 1995;83:1194-204.
147. Koska AJ, 3rd, Romagnoli A, Kramer WG. Effect of cardiopulmonary bypass on fentanyl distribution and elimination. *Clin Pharmacol Ther* 1981;29:100-5.
148. Schwartz AE, Matteo RS, Ornstein E, Young WL, Myers KJ. Pharmacokinetics of sufentanil in obese patients. *Anesth Analg* 1991;73:790-3.
149. Shibutani K, Inchiosa MA, Jr., Sawada K, Bairamian M. Accuracy of pharmacokinetic models for predicting plasma fentanyl concentrations in lean and obese surgical patients: derivation of dosing weight ("pharmacokinetic mass"). *Anesthesiology* 2004;101:603-13.
150. Jiko M, Yano I, Okuda M, Inui K. Altered pharmacokinetics of paclitaxel in experimental hepatic or renal failure. *Pharm Res* 2005;22:228-34.
151. Pai MP. Estimating the Glomerular Filtration Rate in Obese Adult Patients for Drug Dosing. *Adv Chronic Kidney Dis* 2010;17:e53-e62.
152. Ribstein J, du Cailar G, Mimran A. Combined renal effects of overweight and hypertension. *Hypertension* 1995;26:610-5.
153. Marik P, Varon J. The obese patient in the ICU. *Chest* 1998;113:492-8.
154. Kasiske BL, Crosson JT. Renal disease in patients with massive obesity. *Arch Intern Med* 1986;146:1105-9.
155. Cindik N, Baskin E, Agrad P, Kinik ST, Turan M, Saatci U. Effect of obesity on inflammatory markers and renal functions. *Acta Paediatr* 2005;94:1732-7.
156. Csernus K, Lanyi E, Erhardt E, Molnar D. Effect of childhood obesity and obesity-related cardiovascular risk factors on glomerular and tubular protein excretion. *Eur J Pediatr* 2005;164:44-9.
157. Savino A, Pelliccia P, Giannini C, et al. Implications for kidney disease in obese children and adolescents. *Pediatr Nephrol* 2011.
158. Post FA, Wyatt CM, Mocroft A. Biomarkers of impaired renal function. *Curr Opin HIV AIDS* 2010;5:524-30.
159. Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE. Functional and structural changes in the kidney in the early stages of obesity. *J Am Soc Nephrol* 2001;12:1211-7.
160. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. *Eur J Clin Pharmacol* 1998;54:621-5.
161. Pai MP, Norenberg JP, Anderson T, et al. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. *Antimicrob Agents Chemother* 2007;51:2741-7.
162. Dvorchik BH, Dampousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. *J Clin Pharmacol* 2005;45:48-56.
163. Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. *Cancer Res* 1984;44:1693-7.
164. Schmitt A, Gladieff L, Lansiaux A, et al. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients. *Clin Cancer Res* 2009;15:3633-9.
165. Ekhardt C, Rodenhuis S, Schellens JH, Beijnen JH, Huitema AD. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter? *Cancer Chemother Pharmacol* 2009;64:115-22.

166. Lewis TV, Johnson PN, Nebbia AM, Dunlap M. Increased enoxaparin dosing is required for obese children. *Pediatrics* 2011;127:e787-90.
167. Abernethy DR, Greenblatt DJ, Matlis R, Gugler R. Cimetidine disposition in obesity. *Am J Gastroenterol* 1984;79:91-4.
168. Karlsson E. Clinical pharmacokinetics of procainamide. *Clin Pharmacokinet* 1978;3:97-107.
169. Drusano GL. An overview of the pharmacology of intravenously administered ciprofloxacin. *Am J Med* 1987;82:339-45.
170. Allard S, Kinzig M, Boivin G, Sorgel F, LeBel M. Intravenous ciprofloxacin disposition in obesity. *Clin Pharmacol Ther* 1993;54:368-73.
171. Daley-Yates PT, McBrien DC. The mechanism of renal clearance of cisplatin (cis-dichlorodiammine platinum ii) and its modification by furosemide and probenecid. *Biochem Pharmacol* 1982;31:2243-6.
172. Abernethy DR, Greenblatt DJ, Smith TW. Digoxin disposition in obesity: clinical pharmacokinetic investigation. *Am Heart J* 1981;102:740-4.
173. Reiss RA, Haas CE, Karki SD, Gumbiner B, Welle SL, Carson SW. Lithium pharmacokinetics in the obese. *Clin Pharmacol Ther* 1994;55:392-8.
174. Chagnac A, Herman M, Zingerman B, et al. Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption. *Nephrol Dial Transplant* 2008;23:3946-52.
175. Mortensen A, Lenz K, Abildstrom H, Lauritsen TL. Anesthetizing the obese child. *Paediatr Anaesth* 2011.
176. Koolen SL, Oostendorp RL, Beijnen JH, Schellens JH, Huitema AD. Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer. *Br J Clin Pharmacol* 2010;69:465-74.
177. Greenblatt DJ, Friedman H, Burstein ES, et al. Trazodone kinetics: effect of age, gender, and obesity. *Clin Pharmacol Ther* 1987;42:193-200.
178. Haritos VS, Ching MS, Ghabrial H, et al. Metabolism of dexfenfluramine in human liver microsomes and by recombinant enzymes: role of CYP2D6 and 1A2. *Pharmacogenetics* 1998;8:423-32.
179. Garcia-Martin E, Martinez C, Tabares B, Frias J, Agundez JA. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. *Clin Pharmacol Ther* 2004;76:119-27.
180. Kumar V, Wahlstrom JL, Rock DA, Warren CJ, Gorman LA, Tracy TS. CYP2C9 inhibition: impact of probe selection and pharmacogenetics on in vitro inhibition profiles. *Drug Metab Dispos* 2006;34:1966-75.
181. Yanni SB, Annaert PP, Augustijns P, Ibrahim JG, Benjamin DK, Jr., Thakker DR. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. *Drug Metab Dispos* 2010;38:25-31.
182. Pai MP, Lodise TP. Steady-state plasma pharmacokinetics of oral voriconazole in obese adults. *Antimicrob Agents Chemother* 2011;55:2601-5.
183. Ebner T, Remmel RP, Burchell B. Human bilirubin UDP-glucuronosyltransferase catalyzes the glucuronidation of ethinylestradiol. *Mol Pharmacol* 1993;43:649-54.
184. Palovaara S, Tybring G, Laine K. The effect of ethinylestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. *Br J Clin Pharmacol* 2003;56:232-7.
185. Yamazaki H, Shaw PM, Guengerich FP, Shimada T. Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. *Chem Res Toxicol* 1998;11:659-65.

186. Stanczyk FZ, Roy S. Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids. *Contraception* 1990;42:67-96.
187. Edelman A, Munar M, Elman MR, Koop D, Cherala G. Effect of Ethinyl estradiol/ Levonorgestrel combined oral contraceptive on the activity of Cytochrome P4503A in obese women. *Br J Clin Pharmacol* 2012.
188. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, Yokoi T. A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. *Drug Metab Dispos* 2000;28:1303-10.
189. Brain EG, Yu LJ, Gustafsson K, Drewes P, Waxman DJ. Modulation of P450-dependent ifosfamide pharmacokinetics: a better understanding of drug activation in vivo. *Br J Cancer* 1998;77:1768-76.
190. Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM. Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. *Cancer Chemother Pharmacol* 1989; 25:139-42.
191. Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. *Clin Pharmacokinet* 1996;31:47-64.
192. Horikiri Y, Suzuki T, Mizobe M. Pharmacokinetics and metabolism of bisoprolol enantiomers in humans. *J Pharm Sci* 1998;87:289-94.
193. Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. *Clin Pharmacokinet* 1996;30:263-99.
194. Viriyayudhakorn S, Thitiarchakul S, Nachaisit S, Ho PC, Wanwimolruk S. Pharmacokinetics of quinine in obesity. *Trans R Soc Trop Med Hyg* 2000;94:425-8.
195. Zharikova OL, Fokina VM, Nanovskaya TN, et al. Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide. *Biochem Pharmacol* 2009; 78:1483-90.
196. Jaber LA, Antal EJ, Slaughter RL, Welshman IR. The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics. *Eur J Clin Pharmacol* 1993;45:459-63.
197. Joerger M, Huitema AD, Meenhorst PL, Schellens JH, Beijnen JH. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. *Cancer Chemother Pharmacol* 2005;55:488-96.
198. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. *Cancer Res* 1994;54:5543-6.
199. Masubuchi Y, Hosokawa S, Horie T, et al. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. *Drug Metab Dispos* 1994;22:909-15.
200. McNeil JJ, Louis WJ. Clinical pharmacokinetics of labetalol. *Clin Pharmacokinet* 1984;9:157-67.
201. Hamann SR, Blouin RA, McAllister RG, Jr. Clinical pharmacokinetics of verapamil. *Clin Pharmacokinet* 1984;9:26-41.
202. Echizen H, Eichelbaum M. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. *Clin Pharmacokinet* 1986;11:425-49.
203. Zito RA, Reid PR. Lidocaine kinetics predicted by indocyanine green clearance. *N Engl J Med* 1978; 298:1160-3.
204. Oda Y, Mizutani K, Hase I, Nakamoto T, Hamaoka N, Asada A. Fentanyl inhibits metabolism of midazolam: competitive inhibition of CYP3A4 in vitro. *Br J Anaesth* 1999;82:900-3.
205. Matzke GR, Zhanel GG, Guay DR. Clinical pharmacokinetics of vancomycin. *Clin Pharmacokinet* 1986;11:257-82.

206. Dvorchik B, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H. Population pharmacokinetics of daptomycin. *Antimicrob Agents Chemother* 2004;48:2799-807.
207. Frydman A. Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. *Haemostasis* 1996;26 Suppl 2:24-38.
208. Barras MA, Duffull SB, Atherton JJ, Green B. Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events. *Br J Clin Pharmacol* 2009;68:700-11.
209. Yee JY, Duffull SB. The effect of body weight on dalteparin pharmacokinetics. A preliminary study. *Eur J Clin Pharmacol* 2000;56:293-7.
210. Barrett JS, Gibiansky E, Hull RD, et al. Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. *Int J Clin Pharmacol Ther* 2001;39:431-46.
211. Richards DA. Comparative pharmacodynamics and pharmacokinetics of cimetidine and ranitidine. *J Clin Gastroenterol* 1983;5 Suppl 1:81-90.
212. Zamboni WC, Houghton PJ, Johnson RK, et al. Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion. *J Pharmacol Exp Ther* 1998;284:89-94.
213. Iisalo E. Clinical pharmacokinetics of digoxin. *Clin Pharmacokinet* 1977;2:1-16.
214. Davis JM, Fann WE. Lithium. *Annu Rev Pharmacol* 1971;11:285-302.

